Hair Loss Treatments + Causes | The Complete Guide

3 questions. 5 seconds to find the answers you need.

Comprehensive Guide

The Complete Hair Loss Guide

What’s Happening · What Helps

Hair thinning and hair loss have dozens of causes, but most people are dealing with one of seven. This guide breaks down each type, from androgenetic alopecia to postpartum hair loss, with the science behind why it happens and which hair loss treatments actually hold up under scrutiny. Consider it your go-to reference. Everything is sourced, nothing is sponsored, and your clinician should always be your first stop for diagnosis and prescriptions.

By age 50, about 1 in 2 men and 2 in 5 women show signs of pattern hair thinning. If you’re here, you’re in good company.^35,37

How Strong Is the Clinical Evidence?

All treatment options in this guide have potential to help grow or keep your hair. The S/M/L icons grade how strong and consistent the human research is behind each one.

Strong

Multiple high-quality human trials/meta-analyses.

Well-studied in people; likely to help when used as directed.

Moderate

At least one good RCT (Randomized Controlled Trial) or consistent clinical studies.

Relatively well-studied and works for many, but results are more nuanced and varied.

Limited

Early/small or mainly lab/observational data.

Promising but not proven; Newer technologies or adjunct (secondary support). Doesn’t mean “won’t work.”

Glossary of Hair Loss Key Terms

Decode hair biology

Anagen: Growth phase; the bulb actively builds the hair. Lasts 2 to 7 years on the scalp.
Catagen: Short transition phase; growth stops and the follicle shrinks. About 2 to 3 weeks.
Telogen: Resting phase; the club hair sits parked in the follicle before release. About 3 months.
Exogen: Active shedding of the resting club hair. Normal loss is roughly 50 to 100 hairs per day.
Club hair: A fully formed, detached hair with a white bulb at the root. The hairs you find on your pillow or in the drain.
Telogen lag: Built-in delay (2 to 3 months) between a follicle entering rest and the hair actually shedding. This is why TE peaks months after the trigger.
Anagen effluvium: Rapid hair loss during the growth phase, usually from direct toxicity to the hair matrix (e.g., chemotherapy). Distinct from telogen effluvium.

Hair follicle: Tiny pocket in the skin that grows each hair. Contains the bulb, dermal papilla, and stem cell niche.
Bulb: Growth factory at the base of the follicle. Matrix cells here build the hair fibre and its pigment.
Dermal papilla: The follicle’s command centre. Receives hormonal signals and directs the matrix to grow or rest.
Matrix: Fast-dividing cells in the bulb that produce the hair shaft. Target of anagen effluvium.
Bulge: Stem cell zone on the follicle wall. These cells regenerate the follicle each cycle, which is why non-scarring alopecias can recover.
Sebaceous gland: Makes sebum (oil) that conditions scalp and hair. Overproduction contributes to seborrheic dermatitis.
Cuticle: Outer protective scales on the hair shaft. Lift and erode with heat, chemicals, and friction.
Cortex: Dense keratin layer beneath the cuticle. Main source of strength, elasticity, and colour.
Cystine bonds: Sulphur-based cross-links that give hair its strength. Relaxers and bleach break them, increasing fragility.
Porosity: How easily water and oils move through the hair shaft. Increases with damage as cuticle scales lift.

DHT (dihydrotestosterone): Potent androgen that shortens the growth phase and drives follicle miniaturisation. The central hormone in AGA.
Androgen receptor: DHT‘s binding site in follicle cells. Genetic variation in receptor sensitivity explains why some follicles miniaturise and others don’t.
5-α-reductase: Enzyme (types 1 and 2) that converts testosterone into DHT. Finasteride and dutasteride work by inhibiting it.
Aromatase: Converts androgens to oestrogens locally. Can buffer DHT levels in the follicle. Higher in occipital (back-of-head) follicles.
Oestrogen: Holds more follicles in anagen. The postpartum oestrogen drop is what synchronises the PP shed.
Thyroid hormones (T3/T4): Regulate the hair cycle’s pace. Both hypo- and hyperthyroid states can trigger a telogen wave.
Ferritin: The body’s iron store. Low ferritin limits iron supply to matrix cells, shortening growth and increasing shed.
Cortisol: Stress hormone that can shift follicles from growth to rest. Sustained elevation is a recognised TE trigger.
SULT1A1: Follicle enzyme that activates minoxidil into its working form. Varies between individuals, which partly explains why some people respond and others don’t.

Miniaturisation: The hallmark of AGA. Each cycle, affected follicles produce thinner, shorter hairs until they become barely visible vellus hairs.
Prostaglandins: Lipid signals with opposing roles. PGD2 brakes growth (elevated in balding scalp); PGE2 and PGF2α support it. Cetirizine targets this pathway.
Wnt/β-catenin: Pro-growth signalling pathway that kick-starts anagen. A key target in hair regeneration research.
VEGF: Vascular endothelial growth factor. Promotes blood vessel formation around the follicle. Boosted by minoxidil.
JAK-STAT: Immune signalling pathway hijacked in alopecia areata. JAK inhibitors (baricitinib, ritlecitinib) block it to restore growth.
IFN-γ (interferon gamma): Inflammatory cytokine that drives the immune attack on follicles in AA. Part of the JAK-STAT cascade.
IL-6 (interleukin 6): Pro-inflammatory signal linked to follicle stress. Elevated in balding scalp and in SD-related inflammation. Clascoterone reduces its secretion.
Immune privilege: A protective shield that normally hides the hair bulb from the immune system. When this breaks down, the immune system attacks the follicle, triggering alopecia areata.
Malassezia: Yeast that lives on normal scalp skin. Overgrowth breaks down sebum into irritating free fatty acids, driving the inflammation cycle in seborrheic dermatitis.

Exclamation-mark hairs: Short hairs that are thin at the base and wider at the tip. Found at the edges of AA patches and indicate active disease.
Fringe sign: Preserved short hairs along the frontal hairline in traction alopecia. Their presence suggests the damage is from sustained pull rather than AGA.
Hair-pull test: Gentle tug on ~50 to 60 hairs. Extracting more than 6 per pull suggests active shedding. A simple clinical screening tool.
Dermoscopy: Magnified examination of scalp and hair using a handheld lens. Helps distinguish between hair loss types and assess scarring versus non-scarring patterns.
Vellus hair: Fine, short, barely visible hair. In AGA, terminal hairs progressively miniaturise into vellus hairs over successive cycles.
Terminal hair: Thick, long, pigmented hair. The kind you notice. The goal of AGA treatment is to maintain or restore terminal hair density.
Non-scarring: Hair loss where follicle stem cells survive (AGA, TE, AA). Regrowth is possible because the follicle structure is intact.
Scarring (cicatricial): Hair loss where the follicle is permanently destroyed and replaced by scar tissue. Chronic traction can progress to this stage.

RCT: Randomised controlled trial. Gold standard for testing whether a treatment works. Participants are randomly assigned to treatment or control groups.
Placebo: Inactive look-alike used for comparison. Ensures observed effects come from the treatment, not expectation.
Double-blind: Neither participants nor researchers know who gets the treatment. Reduces bias in both reporting and assessment.
Open-label: Everyone knows the treatment assignment. Results can be influenced by expectation. Weaker evidence than blinded trials.
Systematic review / meta-analysis: Pools data from multiple studies to assess overall evidence. Higher confidence than any single trial alone.
First-line: The preferred starting treatment for a condition based on current evidence. For AGA, this is typically minoxidil and/or a 5-α-reductase inhibitor.
Adjunct: An add-on that supports a main treatment. Microneedling alongside minoxidil is an example of adjunct therapy.

Genetic/Pattern Thinning

Androgenetic Alopecia

Pattern thinning is the most common form of hair loss. If your hair is gradually getting thinner rather than falling out in patches or clumps, this is most likely what you’re dealing with. It affects roughly half of all men and 40% of women by age 50. The driver is genetic sensitivity to DHT, a hormone that shortens each hair’s growth phase cycle by cycle. The follicles aren’t destroyed. They’re miniaturising, not disappearing. That’s why treatment can work, and why choosing not to treat it is equally valid. ^8,9

Mechanism

5-α-reductase converts testosterone to DHT. In genetically susceptible follicles — concentrated at the temples, crown, and mid-scalp — DHT shortens anagen and shrinks follicle output each cycle. Thick hairs are gradually replaced by finer, shorter ones. Non-scarring: the follicle survives. ^8,9

Typical Pattern

Men: receding temples, thinning crown, eventually merging. Women: widening mid-scalp part, frontal hairline usually preserved. No patches, no scarring. Hair just looks thinner — especially under bright light or when wet. ^8,9

Common When

After puberty, progressing with age. Stress, illness, or nutritional gaps can trigger a telogen effluvium shed on top of an existing pattern, causing what feels like sudden worsening. Hormonal shifts (postpartum, perimenopause, contraception changes) can amplify or unmask previously subtle thinning. ^35,37

What to expect

AGA responds slowly. Most treatments need 6 to 12 months before visible change, and maintenance is ongoing.

Month 0

Start treatment. Baseline photos.

Month 1–3

Shedding may increase. This is normal — weak hairs clearing for stronger regrowth.

Month 6

Earliest point for visible improvement. Compare to baseline photos.

Month 12

Full assessment. Clinician review. Adjust protocol if needed.

Ongoing

Maintenance is indefinite. Stopping typically means gradual return of thinning.

Timelines vary by individual. Combination therapy (e.g., topicals + anti-androgen + microneedling) may accelerate response.^6,10

The Science: How miniaturisation works

Androgenetic alopecia comes down to one interaction: DHT binding to androgen receptors in the dermal papilla. When this happens in genetically susceptible follicles, pro-growth signals (VEGF, IGF-1) drop, inhibitory signals rise, the growth phase shortens, and the follicle’s output shrinks a little more each cycle. ^8,9

This is miniaturisation. A thick terminal hair becomes a thinner one, then a finer one, then eventually a wispy, translucent vellus-like strand. It happens follicle by follicle, cycle by cycle — which is why most people don’t notice until significant ground has been lost. ^8,9

The pattern of pattern thinning

Not every follicle is equally susceptible. The temples, crown, and mid-scalp have higher concentrations of 5-α-reductase (the enzyme that converts testosterone to DHT) and more sensitive androgen receptors. The back and sides of the head have lower enzyme activity and higher aromatase, which converts androgens to oestrogens, buffering the DHT signal. That’s why those areas are typically spared, and why they’re used as donor sites in hair transplantation. ^8,9

The pattern varies by sex and ethnicity. Men tend to lose ground at the temples and crown first (Norwood-Hamilton scale). Women more commonly thin diffusely across the mid-scalp while keeping their frontal hairline (Ludwig or Sinclair scales). These are generalisations — some women develop bitemporal recession, some men thin diffusely. ^8,9,35

Prevalence is highest in Caucasian men and lower in East Asian, African, and Native American populations, though it occurs across all groups. Distribution patterns vary too. Inheritance is polygenic — many genes contribute rather than one — so predicting severity from family history alone is unreliable. ^35,37

How to spot AGA

Pattern thinning doesn’t announce itself. There isn’t dramatic shedding, or patches, or redness. Instead, you’ll notice hair that looks thinner under bright light, a part that’s slowly widening, a ponytail that doesn’t feel as thick. Wet hair shows more scalp than it used to. In men, the hairline may be creeping back at the temples without any clear starting point. ^8,9

Most people describe a moment of realisation rather than a moment of onset — a photo, a glimpse in the mirror in harsh lighting, or someone else’s comment. The defining feature isn’t hairs falling out. It’s new hairs coming in finer and shorter than the ones they replaced. ^8,9

Why a small change in diameter matters a lot

Visible coverage comes from bulk: thickness multiplied by length. A hair half the diameter of its predecessor doesn’t give you half the coverage — it gives you roughly a quarter, because visual bulk drops exponentially as the shaft gets thinner. Shorter growth phases compound this by preventing hairs from reaching a useful length. The result is wider parts and more visible scalp, even when the actual number of follicles hasn’t changed much. ^8,9

Why timing matters — and what speeds things up

Miniaturisation is cumulative. Each cycle, anagen shortens, telogen stretches, and the emerging fibre gets finer. The process is non-scarring — follicles persist — but the longer it progresses, the harder it becomes to coax them back into producing thick, visible hair. A follicle that’s been miniaturising for two years still has more to work with than one that’s been at it for ten. ^8,9

Progression isn’t always linear. Slow plateaus and sudden spurts are both common. Overlapping triggers — telogen effluvium from illness, stress, or nutritional deficiency — can temporarily accelerate visible thinning on top of an existing pattern, making it look like things have worsened overnight when two separate processes are happening at once. ^8,9,35

Perimenopause and hair thinning

Through the menopausal transition, oestrogen and progesterone fluctuate and trend downward. The follicle sees a relatively stronger androgen influence as a result. In susceptible areas like the mid-scalp and vertex, this amplifies DHT signalling: pro-growth cues drop, anagen shortens, and shafts gradually miniaturise. Hormonal swings can also trigger telogen sheds on top of the pattern thinning, so the loss comes in waves rather than a steady progression. ⁴⁹

Male pattern hair loss

Male pattern baldness affects around 50% of men by age 50 and up to 70% over a lifetime. It is one of the most common things a human body does. The classic progression — temples recede, crown thins, the two eventually merge — is well recognised, but the experience is more varied than the diagrams suggest. Some men notice it in their early twenties. Others not until their forties or fifties. Some plateau. Others don’t. ^35,37

There’s no obligation to treat it. Shaving, adjusting your style, or not minding are all legitimate responses. For those who do want to intervene, the earlier you start, the more you have to work with. ³⁷

How recovery works

There are two main levers:

Prolong the growth phase — keep follicles in anagen longer so hairs have time to grow thicker and reach a visible length.
Reduce DHT signalling — lower the hormonal pressure that’s driving miniaturisation in the first place.

Most effective protocols combine both. Growth stimulants like minoxidil address the first. Anti-androgens like finasteride or dutasteride address the second. Adjuncts like microneedling, cosmetic topicals, and low-level light therapy can enhance the response. The typical trajectory: stabilise first, then recover visible density as miniaturised follicles produce progressively thicker hairs over successive cycles. ^8,9

You don’t have to wait until thinning is obvious. Starting a topical early can help maintain what you have before miniaturisation gets ahead of you. Prevention is always easier than reversal. See Topical Treatments for what you can start on your own, and Medical Interventions for what requires a clinician.

Minoxidil (topical) — a potassium-channel opener that raises pro-growth cues (e.g., ↑VEGF). It lengthens anagen and enlarges miniaturising follicles, adding diameter and coverage with steady use. Best started early and kept up. S ^6,10
Topical Retinoids (tretinoin/retinal/retinol) — vitamin-A derivatives that normalise follicular turnover (lift compact scale), improve penetration of leave-ons, and can up-regulate SULT1A1—the enzyme that activates minoxidil. Via RAR/RXR signalling they also support keratin/ECM genes and ease inflammation, supporting growth. In trials, once-daily 5% minoxidil + 0.01% tretinoin ≈ twice-daily minoxidil. M ^79-83
Adenosine — activates A₂-type receptors in dermal papilla cells, boosting pro-growth signals (FGF-7/KGF, VEGF). This can prolong anagen and thicken hair shafts; small RCTs report measurable calibre gains and fuller appearance. M ^5,12
Caffeine — may dampen DHT-related signalling at the follicle (lab data) and modestly support hair regrowth in small human studies; it may also encourage local microcirculation. Best used in leave-on formulas applied consistently. L ^13,44
Red / near-infrared light therapy (LLLT/photobiomodulation) — home devices (usually caps) that treat the scalp with red (~630–680 nm) and near-infrared (~780–870 nm) light. Used consistently a few times per week, meta-analyses show modest density gains; best as an adjunct to proven topicals. M ⁶³
Antioxidants + signalling peptides — may temper oxidative stress linked to miniaturisation. May reduce shedding and increase perceived hair fullness. Includes but not limited to: L ¹⁴
- Ginsenosides — studied for ginseng and hair growth (standardised Panax ginseng extracts; e.g., Rg3, Rb1); preclinical signals for dermal-papilla support (proliferation, Wnt/β-catenin) and mild 5-α-reductase modulation. ⁴³
- Melatonin (topical) — circadian/antioxidant signalling. Small human trials report higher anagen ratio, density, and hair shaft thickness. ^46,74
- Procyanidin B2 (apple polyphenols) — randomized studies show gains in hair count/diameter in men. Works as an antioxidant and growth-signal modulator. ^75,76
- Peptides (e.g., GHK-Cu; acetyl tetrapeptide-3; biotinoyl tripeptide-1) — early, mostly manufacturer-sponsored signals for extracellular-matrix/anchoring-protein support and anti-inflammatory cues. ^77,78
Barrier support (prebiotics · panthenol · soothing agents) — reinforces the scalp’s barrier and microbiome, reducing irritation and micro-inflammation. A calmer scalp tolerates leave-ons better and maintains a healthier environment for follicle vitality. L

Oral anti-androgens (finasteride/dutasteride; 5-α-reductase inhibitors) — daily tablets that lower scalp DHT. For many (especially men), this slows loss and can thicken hair over months. Also useful for perimenopausal pattern thinning where relative androgen influence rises. In women, use is off-label; effective contraception is required and it’s contraindicated in pregnancy/trying to conceive. S ^11,47,66,49
Topical anti-androgen (clascoterone 5% solution) — blocks DHT at the follicle’s androgen receptor without meaningful systemic absorption. Two large phase III trials (1,465 men) showed statistically significant hair-count increases versus vehicle, with a safety profile comparable to placebo. Not yet approved for AGA; regulatory submissions are expected in 2026. M ^87,88
Low-dose oral minoxidil — for cases where topical therapy isn’t enough or isn’t tolerated. It can increase density but requires blood-pressure and side-effect monitoring and may cause unwanted facial/body hair. For women, it’s often paired with a 5-α-reductase inhibitor and home LLLT during the perimenopausal transition (off-label combination). M ^6,65,63,49
Topical cetirizine (1% solution) — an antihistamine applied to the scalp that inhibits prostaglandin D2, a growth-phase brake elevated in balding follicles. Small RCTs show increased hair density and diameter versus placebo, though less effective than minoxidil as a standalone. Targets a different pathway, so may suit non-responders to minoxidil or work as an adjunct. L ^89,50
Platelet-rich plasma (PRP) — your own platelets concentrated and injected into the scalp. Many patients see thicker strands, but results depend on protocol and provider—choose experienced centers. M ⁶⁴
Microneedling + topicals — controlled micro-injury that can enhance topical responses (studied with minoxidil and, more recently, cetirizine). Best done on a schedule set by a trained clinician. M ^15,51
Surgery — hair transplantation for advanced, stable patterns when medical therapy isn’t enough. Expect ongoing medical maintenance to protect non-transplanted hair. M ⁸

Building your approach

AGA treatment works best as a stack rather than a single product. Most clinicians build a protocol in layers, and the logic is straightforward: target multiple parts of the problem at once.

A typical starting point is a growth stimulant (topical minoxidil) combined with something to reduce DHT impact (finasteride, dutasteride, or a topical anti-androgen). From there, adjuncts like microneedling, low-level light therapy, or cosmetic topicals can be layered in based on your response and tolerance. Each targets a different mechanism, which is why combination therapy consistently outperforms monotherapy in trials. ^5,10,11,14

There’s no single correct protocol. Your combination depends on your pattern, how far things have progressed, whether you prefer topical or systemic options, your tolerance for side effects, and what you’re willing to maintain long-term. The point is to be intentional about it rather than trying random products and hoping something sticks.

If you’re not sure where to begin: start with what has the strongest evidence and the lowest barrier. For most people, that’s topical minoxidil. Build from there. ^5,10,11,14

What maintenance actually looks like

The word “maintenance” can sound exhausting when you’re just starting out, but it’s all about routine.

This might look like: apply a topical once in the evening (60 seconds), take meds in the morning if you’re on oral treatment (5 seconds), and use a device like an LLLT cap a few times a week while you’re watching TV or working (15–20 minutes).^6,63

The first month tends to feel like the most effort because everything is new. The key insight is that consistency beats perfection every time. Missing a day here and there doesn’t reset your progress. What matters is the long-term pattern.

Reading the signals

This is the hardest part of AGA treatment: figuring out whether it’s working.

Months 3–6: Shedding should stabilise. You may not see visible improvement yet, and that’s normal. The new hairs are growing but haven’t reached a noticeable length. This is the patience window.
Month 6: First realistic checkpoint. Compare to your baseline photos taken in the same lighting. Look for changes in part width, hairline density, and overall volume. Even subtle changes at six months are a positive signal.
Month 12: Full assessment point. If you’re seeing improvement, your protocol is working. If things have stabilised but not improved, discuss adding or adjusting with your clinician. If nothing has changed or things have worsened, it’s time to reassess the approach entirely.
Ongoing: Periodic shedding phases can happen even on treatment — seasonal variation, stress, illness. A bad week or even a bad month doesn’t mean your treatment has stopped working. Look at the trend over quarters, not days.

Monthly photos in consistent lighting provide the most reliable tracking. Checking the mirror every single day and counting hairs left in the drain usually create more anxiety than useful data.

Working with your clinician

If you haven’t seen a dermatologist yet, here’s what to expect. A good first appointment for hair loss should include a scalp examination (ideally with dermoscopy), a discussion of your family history and timeline, and possibly blood work to rule out contributing factors like iron deficiency or thyroid dysfunction. ^69,84

Things worth asking:

What classification would you give my current pattern and stage?
What’s your recommended first-line approach, and why?
What should I expect in the first 3–6 months?
When should I come back for a progress check?
Are there any tests you’d recommend before starting treatment?

While AGA is incredibly common, it is treatable, and the evidence base for intervention is strong.

If you’re already on a protocol: expect annual or biannual check-ins. Bring recent photos. If you’re not happy with progress, ask whether your current approach still makes sense or whether it’s time to adjust.

The bigger picture

Pattern thinning moves slowly, so the psychological weight builds slowly too. The mental load is real and well-documented, and you deserve support. ³⁷

Whether you treat it or not is a legitimate choice either way. What’s worth paying attention to is whether hair loss is reshaping your day-to-day life.

The hair and how you feel about the hair are two separate things. If constantly thinking about the hair is wearing you down, it’s worth talking with someone.

Excess Shedding (Stress-Related Hair Loss)

Telogen Effluvium

A common, temporary form of hair loss where a stressor pushes more follicles into the resting phase at once, causing them to shed as a wave. Triggers include illness, surgery, iron or thyroid shifts, medication changes, and major stress. Shedding typically peaks 2 to 3 months after the event, then thickness rebuilds over the following 3 to 6 months. ^1,2

Mechanism

A systemic stressor synchronises a large share of follicles into telogen (resting phase). Shedding peaks 2 to 3 months later due to the built-in telogen lag. Follicle stem cells remain intact, so regrowth begins once the trigger resolves. ^1,2

Typical Pattern

Diffuse shedding across the entire scalp. The scalp looks healthy with no distinct bald patches. A standardised hair-pull test (grasp ~50 to 60 hairs) is often positive during active shedding, with more than 6 hairs extracted per pull. ^1,2

Common When

After illness or fever, surgery, rapid weight loss, childbirth (oestrogen drop), iron deficiency, thyroid dysfunction, or medication changes. Any transient systemic shift that pushes follicles into telogen together. ²

What to expect

TE has a built-in arc. The trigger has usually passed by the time shedding peaks, and recovery follows naturally.

Trigger event

Illness, surgery, stress, deficiency, or medication change.

Month 2–3

Peak shedding. This is the telogen lag — hairs that entered rest weeks ago are now falling.

Month 3–6

Shedding slows. New growth begins. Short fine hairs appear at the hairline.

Month 6–9

Visible recovery. Density rebuilds as new hairs reach noticeable length.

If shedding persists beyond 6 months, check for an ongoing trigger (iron, thyroid) or underlying pattern thinning with your clinician.

The Science: A temporary reset

Telogen effluvium is a temporary, non-scarring form of hair loss. Something stresses the body, and a larger-than-normal share of follicles leave growth (anagen) and enter the resting phase (telogen) at the same time. Weeks later, they shed as a wave. No follicles are permanently damaged — once the trigger resolves, they’re fully capable of producing normal, full-sized hairs again. ¹

Why it happens

TE is a stress response. Systemic signals push follicles out of growth together, so they shed as a wave rather than on their usual staggered schedule. Common triggers include:

Major illness or fever — inflammatory cytokines prematurely push follicles into telogen as the body diverts resources toward immune recovery.
Surgery or acute physical stress — anaesthesia, blood loss, and a cortisol surge synchronise telogen entry.
Childbirth — the sharp post-delivery drop in oestrogen releases hairs that pregnancy held in extended growth, so many enter telogen together.
Thyroid shifts — both hypo- and hyperthyroidism disrupt anagen maintenance and increase the telogen fraction.
Iron deficiency — low ferritin limits the rapidly dividing matrix cells that build hair, shortening anagen and increasing shed.
Rapid weight loss or low nutritional intake — energy, protein, or essential fatty-acid deficits lower growth signals, tipping follicles out of anagen.
Medication changes — certain drugs (oral retinoids, β-blockers, anticoagulants, SSRIs, among others) can shift follicles into telogen as a side effect.
Psychological stress — HPA-axis activation and stress neuropeptides nudge follicles toward catagen.

Shedding typically peaks around 2 to 3 months after the trigger and settles as cycles resynchronise. If shedding is heavy or prolonged, iron and thyroid levels are worth investigating early. ^1,2

Why shedding shows up months later

Hair doesn’t grow continuously. Each follicle cycles through a growth phase (anagen), a brief transition (catagen), and a resting phase (telogen) before shedding and starting over. Normally these cycles are staggered across the scalp, so daily shedding is spread out and barely noticeable. In TE, a trigger synchronises the shift to telogen across many follicles at once. But those hairs stay anchored for several more weeks before actually releasing. That’s why the noticeable shed peaks 2 to 3 months after the event, not during it. ^1,2

What you’ll see

More hairs on your brush, in the drain, on your pillow — coming from all over the scalp rather than one specific area. This even, all-over pattern is called diffuse shedding. The scalp itself looks healthy, with no distinct bald patches and no scarring. ¹

That’s what separates TE from the other types covered in this guide. There are no smooth round patches (alopecia areata), no concentration at the temples or crown (pattern thinning), no redness or flaking (scalp inflammation). It’s just more hair coming out, from everywhere, all at once. ^1,2

When it’s more than one thing

Most TE resolves within 6 months. Sometimes it doesn’t. Chronic telogen effluvium is a recognised clinical pattern where diffuse shedding persists beyond 6 months without a clear ongoing trigger. It’s frustrating and poorly understood, but it’s still non-scarring and the follicles remain intact. ³

The other possibility is that the shed has revealed something that was already there. TE can unmask underlying pattern thinning (AGA) that was previously too subtle to notice. The shedding itself is temporary, but once it clears, the thinning that remains doesn’t follow the same recovery arc. If density doesn’t bounce back the way you’d expect, or if the thinning concentrates at the part or temples rather than staying diffuse, it’s worth investigating with your clinician. ^3,7

How recovery works

Once the trigger resolves, follicles re-enter growth on their own staggered timelines. Shedding tapers, short fine hairs appear at the scalp, and coverage gradually rebuilds over 3 to 6 months as those new hairs thicken and lengthen. ^1,2

Minoxidil (topical) — opens potassium channels in follicle cells and boosts local growth signals (VEGF). That keeps hairs in the growth phase longer and helps resting follicles switch back to growth sooner after a shed—gradually thickening strands over months. Especially useful if pattern thinning overlaps. M ^2,4,6,10
Adenosine — binds A_2A receptors in the follicle’s growth center (dermal papilla), activating pro-growth signals (FGF-7/VEGF) and keeping hairs in anagen longer. Small human studies report thicker regrowth and fuller-looking coverage. L ^5,12
Caffeine — can counter testosterone-related growth suppression in follicles (lab data; ↑cAMP/anti-androgenic signaling). As a leave-on or shampoo adjunct, caffeine for hair regrowth may modestly trim day-to-day shedding perception and support earlier recovery while the trigger settles. L ^13,44
Keratolytics (salicylic acid) — lift adherent scale/product build-up so leave-ons contact the scalp better—especially on oily scalps. A clear follicle opening can make it easier for new growth to break through. L²⁷
Barrier + microenvironment support (panthenol · ectoin · prebiotics · peptides · urea) — rebuilds the scalp’s moisture/lipid barrier and calms inflammation. A steadier barrier means less itch and flake (so less scratching/breakage), better tolerance of leave-on actives (easier to stay consistent), and a healthier follicle environment while cycles reset. L
Antioxidants (polyphenols · tocopherol nicotinate · ginsenosides) — combat oxidative stress and calm inflammation around follicles, helping the scalp environment reset after a shed. These can support anagen re-entry and local microcirculation. Research on ginseng and hair growth shows that ginsenosides boost VEGF, while tocopherol nicotinate supports capillary function—making regrowth phases more efficient. L ^14,43
Melatonin (topical) — a nighttime leave-on that acts as an antioxidant and signals follicle melatonin receptors to steady the hair-cycle timeline, keep hairs in growth longer, and calm micro-inflammation while triggers resolve. L ^46,74

Evaluate + correct systemic drivers — Most cases of Telogen Effluvium resolve once the stressor passes. When shedding is prolonged or severe, targeted evaluation (iron deficiency, thyroid dysfunction) is appropriate. S ^2,7
Stimulatory support — oral minoxidil may be used short-term if recovery is slow or if pattern thinning overlaps M ⁴⁰.

Reading the signals

TE is unsettling because the shedding feels urgent but the timeline is slow. Here’s how to read what’s happening:

The lag: Whatever triggered the shed happened 2 to 3 months before the hair started falling. By the time you notice increased shedding, the trigger has usually already passed. This means the worst of the shedding often coincides with the beginning of recovery, not the start of the problem.
Peak vs plateau: Shedding typically peaks around months 2–3 post-trigger, then gradually tapers. If you’re tracking hair fall, look for a downward trend over weeks rather than day-to-day changes. ^1,3
New growth signs: Short, fine hairs appearing at the hairline and part line are a strong signal that follicles are cycling back into growth. These baby hairs are easy to miss but they’re the most reassuring indicator that you’ve turned a corner.

If shedding persists beyond 6 months, the picture may be more complex. Chronic TE exists, and TE can also unmask underlying AGA that was previously too subtle to notice. ^3,7

Working with your clinician

TE often resolves on its own once the trigger passes, so not everyone needs clinical intervention. But there are times when it’s worth getting checked:

Shedding that persists beyond 6 months
No obvious trigger you can identify
Shedding that feels disproportionate to the trigger
Signs of thinning in a pattern (part width, temples) rather than diffuse all-over shedding
Fatigue, weight changes, or other systemic symptoms alongside the shedding

Blood work for ferritin, thyroid function, and a general metabolic panel can rule out ongoing drivers. If your clinician suspects AGA overlap, dermoscopy can help distinguish the two. ^1,3,7

Supportive topicals (caffeine, peptides, antioxidant serums) won’t speed up follicle cycling, but they can protect the new hairs coming through. Think of them as fibre support during recovery.

The bigger picture

TE is disorienting because it often hits without warning. You’re pulling clumps from the shower drain and trying to reverse-engineer what happened 2 to 3 months ago. The uncertainty can consume more headspace than the shedding itself.

TE is self-limiting for most people. But knowing that it’ll probably grow back doesn’t make the interim easier. If the anxiety around shedding is significantly adding to daily stress, it’s worth talking to someone for support.

Postpartum Shedding

Post-Pregnancy Telogen Effluvium

A specific and very common trigger for telogen effluvium. During pregnancy, elevated oestrogen holds more hairs in growth. After delivery, that support drops and many follicles shift into rest and shedding at once. The shed peaks around 2 to 4 months postpartum, then steadily settles. If shedding feels heavy or lingers, iron and thyroid are worth checking. For most, thickness rebounds with time and gentle care. ^2,38

Mechanism

Pregnancy oestrogen holds more follicles in anagen (growth). After delivery, the hormone drop releases them into telogen (rest) together, creating a synchronised shed. As hormones stabilise, follicles re-enter growth on their own timelines. ³⁸

Typical Pattern

Shedding ramps up a few weeks after birth and peaks around 2 to 4 months. Hair loss is diffuse across the scalp, leading to reduced density and a wider-looking part. Early regrowth appears as soft, short fine hairs at the hairline and temples. ³⁸

Common When

First 3 to 6 months postpartum. More noticeable when compounded by iron deficiency, thyroid shifts, or major stress. Can also unmask underlying traction damage or pattern thinning. ^2,38,39

What to expect

Postpartum shedding follows a predictable curve. It feels dramatic but has a clear endpoint for most.

Delivery

Oestrogen drops. Follicles held in growth begin shifting to rest.

Month 2–4

Peak shedding. Can feel alarming — clumps in the shower, hair on everything.

Month 6

Shedding slows. Hormones stabilising. New regrowth starting.

Month 9–12

Density approaching pre-pregnancy levels. Full recovery by ~12 months for most.

Iron and thyroid are worth checking if shedding lingers past 6 months. Breastfeeding can extend the timeline slightly.

The Science: Why it happens

Each hair follicle cycles through growth (anagen), a brief transition (catagen), and rest (telogen) before shedding and starting over. Normally these cycles are staggered, so daily shedding is spread out and barely noticeable. During pregnancy, elevated oestrogen extends anagen and suppresses the usual transition signals. Shedding slows. More follicles stay in growth at the same time. For a lot of people, pregnancy hair is the best their hair has ever looked. ³⁸

After delivery, oestrogen falls sharply. A large share of those follicles shift into telogen at once. The follicles aren’t damaged. This is a temporary, non-scarring reset. As hormones stabilise, they re-enter growth and density trends back toward baseline. ³⁸

Why shedding shows up months later

The shed peaks around 2 to 3 months after delivery. Hairs that shifted into telogen post-delivery stay anchored for several more weeks before actually releasing. By the time shedding is visible, the hormonal trigger has already passed. ^2,38

What you’ll see

You’ll notice it in the shower first. More hair in your hands than feels right, clumps in the drain, strands on everything. It looks alarming because it is a lot of hair. But it’s diffuse — coming from the entire scalp evenly, not concentrated in patches or at the hairline. The scalp looks normal. No redness, no scarring. ³⁸

If your hair felt unusually thick during pregnancy, the contrast makes it worse. You’re not just losing hair — you’re losing the bonus hair that oestrogen held onto. Parts widen, ponytails thin out, and short regrowth starts appearing at the hairline as new cycles kick in. ³⁸

What can make it worse

Postpartum shedding can be amplified by overlapping stressors that independently push follicles toward telogen. If shedding feels heavy or unusually prolonged, these are worth investigating early:

Low ferritin from post-delivery blood loss or insufficient intake. Iron repletion can help the cycle normalise. ²
Postpartum thyroid shifts that disrupt growth-phase timing. ²
Recent illness, major stress, rapid weight loss, or medication changes that compound the telogen signal. ²

Addressing these doesn’t work overnight. Improvement follows hair-cycle timelines — typically 3 to 6 months. ²

When it might be more than postpartum

Sometimes the shed clears and the thinning that remains doesn’t match the pattern. If density isn’t recovering the way you’d expect by 9 to 12 months, or if the thinning concentrates at the part or temples rather than staying diffuse, something else may have been there all along. ^38,39

Postpartum TE can unmask underlying pattern thinning (AGA) that was previously too subtle to notice. It can also reveal traction damage at the hairline from styles worn during or before pregnancy. The shedding itself is still temporary. But what it exposes may need its own approach. ^38,39

How recovery works

As the wave passes, new growth appears as soft fine hairs at the hairline and temples, then fills in elsewhere. Most people return toward their pre-pregnancy baseline over 6 to 12 months, though the pace depends on individual cycle length and whether any amplifiers are still active. Supportive topicals can help protect new growth and create a better environment for recovery — see Topical Treatments for what to consider while breastfeeding. ^2,38,45

Minoxidil (topical) — helps resting follicles switch back to growth. May help shorten the recovery by promoting anagen. Consider only with clinician guidance if breastfeeding. M ^6,10,45
Adenosine — activates A₂-type receptors in dermal papilla cells, boosting pro-growth signals (FGF-7/KGF, VEGF). This may prolong anagen and thicken hair shafts; small RCTs report measurable calibre gains and fuller appearance. L ^5,12
Caffeine — may dampen DHT-related signalling at the follicle (lab data) and modestly support growth in small human studies; it may also encourage local microcirculation. Best used in leave-on formulas applied consistently. L ^13,44
Keratolytics (salicylic acid) — lift adherent scale/product build-up so leave-ons contact the scalp better—especially on oily scalps. A clear follicle opening can make it easier for new growth to break through. L
Antioxidant support (polyphenols · tocopherol nicotinate · ginsenosides) — neutralises oxidative by-products around follicles, calms micro-inflammation, and can support local microcirculation, creating a steadier environment for anagen regrowth. Often reads as a calmer scalp and fuller look over time. L ^14,43
Barrier + microenvironment support (panthenol · ectoin · prebiotics · peptides · gentle cleansing) — soothes irritation, improves tolerance to actives, and keeps scalp comfortable while cycles reset. L

No intervention needed for most cases — postpartum shedding is a temporary, non-scarring cycle reset. In the absence of another diagnosis, medical procedures aren’t indicated. ^2,38
Check iron stores (ferritin) — ask for ferritin with a CBC ± iron studies if shedding is heavy, atypical, or lingers. Post-delivery iron depletion is common; repleting iron under clinician guidance helps the cycle normalise over the following months. ²
Screen thyroid — request TSH (± free T4) to rule out postpartum thyroiditis, which can push follicles into telogen. Treat per endocrine guidance and re-check as levels stabilise. ²
Review new meds with your clinician — some postpartum prescriptions can temporarily bump shedding. Don’t change meds on your own. If shedding is significant, note when shedding began vs. new meds and bring that timeline to your visit. ^2,72
- Hormonal contraception — shifts in oestrogen/progestin can cue a telogen wave; more androgenic progestins may unmask pattern-type thinning in the predisposed.
- Antidepressants (SSRIs/SNRIs, bupropion) — uncommon, idiosyncratic telogen effluvium after a start or dose change.
- Blood-pressure meds (labetalol; occasionally other β-blockers) — can encourage follicles toward telogen.
- Anticoagulants (heparin, warfarin) — diffuse shed sometimes appears 1–3 months after initiation.
- Thyroid therapy (levothyroxine titration; β-blockers for hyper symptoms) — the correction phase itself can briefly increase shed.
Most med-related shedding is a timing shift—more follicles enter rest together—so it shows 6–12 weeks after a medicine change and is usually temporary.

What care looks like during recovery

Your body is already fixing this. The follicles need to cycle through the telogen wave triggered by the oestrogen drop after delivery, and that process has its own pace. Supportive topicals can help protect and nourish new growth, but the timeline is largely hormonal. ³⁸

What you can do is protect what’s growing back. Soft detangling, loose styles, minimal heat — reducing breakage lets new growth reach a visible length instead of snapping off. ^38,39

It may be worth checking iron and ferritin levels. Pregnancy draws heavily on stores, and low ferritin can extend the shed independently of the hormonal piece. ^38,39

Reading the signals

Postpartum shedding follows a predictable timeline, although it may not feel predictable. Watch for these things:

Months 2–4 post-delivery: Peak shedding. This is the telogen wave arriving. It can feel alarming — clumps in the shower, hair on everything — but it’s the body catching up, not an escalation.
Month 6: Shedding should be noticeably slowing. New growth appearing as short, fine hairs at the hairline and part.
Month 9–12: Density approaching pre-pregnancy levels for most. Full recovery typically takes about 12 months. Breastfeeding can extend the timeline slightly.

If shedding persists beyond 12 months, there’s no visible regrowth, or new patterns emerge (widening part, temple recession), there may be more to the picture. Postpartum hormonal changes can unmask pre-existing AGA that was previously masked by pregnancy’s extended anagen. Your clinician can distinguish between the two with dermoscopy. ^2,38

The bigger picture

Postpartum shedding arrives at one of the most physically and emotionally demanding periods of your life. You’re sleep-deprived, adjusting to a new identity, and your hair is falling out. The timing is brutal.

If you’re experiencing broader mood changes alongside the increase in shedding — persistent low mood, anxiety, disconnection — talk to someone. Hair loss is stressful and can amplify postnatal depression, and you deserve support.

Patchy Autoimmune

Alopecia Areata

An autoimmune form of hair loss where the immune system targets growing hair follicles. It’s non-scarring: the follicles remain intact, so regrowth is possible. It typically presents as smooth, round bald patches, but can also cause broader thinning or loss of brows and lashes. Flares can come and go. Early, consistent treatment helps limit spread and speed recovery. ^16,22

Mechanism

The follicle’s immune privilege breaks down, allowing NKG2D⁺ CD8⁺ T-cells and IFN-γ/JAK-STAT signalling to attack anagen bulbs and halt growth. Stem cells survive, preserving the potential for regrowth. ^19,22

Typical Pattern

Sudden, well-defined round or oval bald patches with smooth skin. “Exclamation-mark” hairs (thin at the base, wider at the tip) at patch edges indicate active disease. Nail pitting may also be present. ^17,22

Common When

Can start at any age. Often runs in families with autoimmune conditions. The course is typically relapsing-remitting: patches can resolve, then new ones appear, making progression feel unpredictable. ^16,22

What to expect

AA is unpredictable. It can resolve on its own, respond to treatment, or flare again. The timeline below represents a typical treatment cycle, not a guaranteed sequence.

Flare

New patch(es) appear. Clinician assessment and treatment plan.

Month 1–3

Treatment begins. Patches may stabilise or expand before responding.

Month 3–6

Earliest regrowth. Often appears as fine, white vellus hairs that gradually pigment.

Monitoring

Ongoing vigilance. New flares can emerge while other patches recover.

Relapsing-remitting course — this cycle may repeat

About 50% of limited AA cases resolve within a year, with or without treatment. Extensive disease is harder to predict.

The Science: What AA is

Alopecia areata is an autoimmune condition. Your immune system misidentifies growing hair follicles as threats and attacks them. Growth stalls, and hair falls out in smooth, sharply outlined patches. ^16,22

The follicles stay intact. They’re not destroyed or scarred. That’s the key distinction. AA shuts growth down, but it doesn’t dismantle the machinery. Once the immune response settles, those same follicles can produce normal hair again. ^16,22

What’s happening underneath

Hair follicles normally have a built-in protection that keeps the immune system from targeting them during growth. In AA, that protection breaks down. Immune cells accumulate around the hair bulb, release inflammatory signals, and shut down the growth cycle. ^19,22

Here’s what that looks like at a cellular level. A specific type of immune cell (CD8⁺ T-cells) swarms the hair bulb and releases interferon-gamma, a signal that tells surrounding tissue the area is under attack. This triggers a chain reaction through a pathway called JAK-STAT, which amplifies the immune response and locks the follicle out of growth. Understanding this pathway matters because it’s the direct target of newer medications (JAK inhibitors) that can interrupt the cycle. See Medical Interventions for more. ^19,22

What you’ll see

Smooth, round patches with sharp borders and otherwise normal-looking skin. At the edges of an active patch, you may notice short “exclamation-mark” hairs: wider at the tip, tapered near the scalp. Fingernails can develop tiny pits or fine vertical ridges. ^17,22

When regrowth begins, it typically starts as soft, fine peach-fuzz that may appear white or lighter than your usual colour before gradually thickening and regaining pigment. ^17,22

Why it comes and goes

AA is typically relapsing-remitting. Patches can flare, resolve, then flare again. Even after full regrowth, the same immune trigger can reactivate. There’s no reliable way to predict when or whether a flare will happen. ^16,19,22

How widespread the loss is at onset is one of the stronger predictors of persistence. A few small patches often resolve on their own or with treatment. Extensive loss — much of the scalp, brows, lashes — tends to be harder to manage and more likely to recur. But even extensive cases can see meaningful regrowth with time and the right intervention. ^16,19,22

How recovery works

When the immune attack subsides, follicles re-enter growth. Early regrowth appears as soft, lighter baby hairs. Over weeks to months, melanocytes catch up and shafts thicken toward their usual diameter. ^16,19,22

Treating active flares early makes a difference. Shutting down the immune response sooner limits how far patches spread and gives follicles a shorter gap to recover from. The stem cells survive even prolonged flares, so the potential for regrowth persists. But the longer a follicle sits dormant, the slower and less predictable that return tends to be. ^16,19,22

Minoxidil (topical) — does not treat the autoimmune driver, but by prolonging anagen (growth) it can accelerate visible fill-in at the edges of clearing patches and hairlines when used consistently. L ^6,16,22
Cosmetic camouflagers (hair fibres · tinted powders · brow pens) — immediately reduce scalp/skin–hair contrast so patches are less noticeable while regrowth catches up. L ¹⁶
Barrier support (soothing agents · antioxidants · peptides · prebiotics · gentle cleansers) — aims to calm itch and limit treatment-related irritation to improve comfort and adherence. Maintaining a healthy scalp microenvironment creates the most favourable conditions for regrowth once immune activity subsides or treatment takes effect. L

Topical corticosteroids (Rx creams/foams like clobetasol) — anti-inflammatory medicines applied to the patch that calm the local T-cell attack on the hair bulb (they suppress the immune signal to create a permissive environment for regrowth, rather than directly stimulating follicles). Best for small, new areas; typically used once daily for 4–8 weeks, then tapered or paused to limit skin thinning/irritation—use extra caution on face/brows. Often jump-starts regrowth and eases itch. S ^16,20
Intralesional corticosteroids (tiny triamcinolone injections into the patch) — same goal as topical steroids, but delivered straight to the hair bulb. By concentrating the anti-inflammatory effect around the follicles, they better “quiet” the immune attack and can jump-start regrowth in small, recent patches. Typically repeated every 4–6 weeks; early stubble may appear in 4–12 weeks if follicles are viable. Possible temporary skin thinning/indentation or lightening—careful dosing is important. Chosen when a faster, targeted option is preferred or when topicals aren’t enough. Not suited to widespread loss or children. S ^16,18
Contact immunotherapy (DPCP/SADBE) — deliberately triggers a mild allergic rash on bald areas to “reset” local immunity. After initially triggering the rash, a tiny dose is applied weekly and adjusted to keep a light reaction. Over many weeks this can calm the attack and allow regrowth. Used for widespread or recurring AA. May cause itch, small blisters, swollen glands, skin-color change. Not use during pregnancy. Results vary and some require repeat maintenance. M ²¹
Calcineurin inhibitors (tacrolimus/pimecrolimus; Rx, off-label) — non-steroid creams that quiet T-cell signals without thinning skin, so they’re useful on delicate areas (brows, eyelids, hairline). Results vary; often used for small patches or maintenance. L ¹⁶
Anthralin (dithranol) (Rx) — short-contact “irritant” therapy that can jump-start regrowth, often used in children. M ¹⁶
Targeted JAK inhibitors (systemic) — interrupts the IFN-γ/JAK-STAT loop in moderate–severe cases; requires specialist oversight and safety monitoring. M ¹⁹
Baricitinib & ritlecitinib (oral JAK inhibitors) — targeted immunomodulators: baricitinib inhibits JAK1/2; ritlecitinib inhibits JAK3/TEC. They quiet the IFN-γ/IL-15–driven JAK-STAT loop and reduce the CD8⁺ T-cell attack on hair bulbs, which can allow regrowth in severe alopecia areata. Both are approved for severe AA in several regions. M ^19,57–62

Building your approach

AA treatment is staged by severity, so it differs significantly from AGA protocols. Your clinician will match the approach to how much hair is affected and how quickly it’s progressing.

Limited disease (a few small patches): Typically starts with topical or intralesional corticosteroids. The goal is to suppress the local immune flare and let the follicle resume growth. ^16,22
Expanding or non-responding patches: Clinicians may add topical immunotherapy (DPCP) or short-course oral corticosteroids to reset a broader immune response. ^16,22
Moderate to severe AA (large or multiple patches, ophiasis pattern, alopecia totalis/universalis): JAK inhibitors (baricitinib, ritlecitinib) have changed the treatment landscape. These target the IFN-γ–driven immune attack directly and have shown meaningful regrowth in clinical trials. They’re systemic medications with monitoring requirements, so the decision to start one involves weighing response likelihood against long-term commitment. ²²

Relapses are unfortunately part of the disease, and they don’t mean treatment isn’t working. Many clinicians keep a standing plan: start topical steroids immediately on any new patch, escalate if it doesn’t stabilise within 4 to 6 weeks. Having this plan in place before a flare happens reduces both the clinical and psychological impact. ^16,22

Reading the signals

AA is harder to read than most hair loss types because its course is inherently unpredictable. But there are markers worth watching:

Early regrowth often appears as fine, white vellus hairs that gradually thicken and gain pigment. This can take 3 to 6 months from the start of treatment. Their presence is a strong positive sign even if they don’t look like much yet.
Exclamation-mark hairs (short, thin at the base, wider at the tip) at the edges of a patch indicate active disease. If you’re seeing these, the flare is still progressing and it’s worth flagging with your clinician.^17,22
New patches appearing while others recover is common in AA and doesn’t mean treatment has failed. It means the immune system is still active in some areas while calming in others.
Stable patches with no regrowth after 6+ months of treatment may need a change in approach. This is a conversation to have with your dermatologist, not a reason to lose hope.

Working with your clinician

AA benefits from specialist involvement more than most hair loss types. A dermatologist experienced with alopecia areata will be familiar with the treatment ladder and can adjust quickly when things change.

If you’re newly diagnosed, ask about a standing flare plan so you know what to do the moment a new patch appears rather than waiting for an appointment. If you’re being considered for a JAK inhibitor, ask about monitoring requirements, expected timeline to response, and what happens if you stop. ^16,19

For extensive or long-standing AA, ask about clinical trials. The treatment pipeline for AA is more active now than at any point in the past decade, and trial access can provide options beyond what’s currently available.

The bigger picture

AA carries a psychological weight that’s disproportionate to how it’s sometimes treated in clinical settings. Patchy, unpredictable hair loss — especially when it affects visible areas like the hairline, brows, or lashes — can trigger intense self-consciousness, social withdrawal, and anxiety about when the next patch will appear.

This is one of the hair loss types where psychological support is clinically justified. Studies show elevated rates of anxiety and depression in AA populations, particularly in extensive or recurrent disease. ¹⁶ Support groups, cognitive behavioural therapy, and counselling can all help. So can honest conversations with people you trust.

Scalp Inflammation + Dandruff

Seborrheic Dermatitis

A chronic, relapsing scalp condition driven by Malassezia yeast overgrowth and a compromised barrier. It causes inflamed skin, greasy scale, and persistent itch. Flares can increase day-to-day shedding and make hair feel less securely anchored. Calming the scalp typically lowers shed counts and improves perceived fullness. Antifungal treatments help, but maintenance is key because relapses are common. ^23–25,32

Mechanism

A weakened barrier combined with Malassezia overgrowth leads to the release of irritating free fatty acids from sebum, which provoke inflammation, itch, and flaking. ^23,24

Typical Pattern

Greasy yellowish scale over red, inflamed skin on the scalp, brows, beard, and behind the ears. Persistent itch is common. Flares tend to worsen with stress, illness, and cold or dry weather. ²³

Common When

Adolescents and adults. Clinical seborrhoeic dermatitis affects 3 to 5% of the population, while mild dandruff is far more prevalent (up to 50% by some estimates). More common in males and in certain underlying health conditions. ²³

What to expect

SD is managed, not cured. Treatment brings relief quickly, but maintenance prevents relapse. Think of it as a rhythm rather than a finish line.

Flare

Itch, redness, flaking increase. Start or intensify antifungal treatment.

Week 2–4

Symptoms improve. Flaking and itch reduce noticeably with consistent antifungal use.

Month 2–3

Scalp stable. Step down to maintenance frequency. Shedding normalises.

Ongoing

Maintenance wash schedule. Watch for seasonal flares (winter, stress, illness).

Flare-maintain cycle — relapses are normal, not failure

Stopping maintenance too early is the most common reason for relapse. A reduced-frequency medicated wash schedule is usually enough to keep flares away.

The Science: What’s happening

Seborrhoeic dermatitis is a chronic, relapsing pattern of scalp inflammation. It involves a compromised barrier, a reactive immune response, and the lipid-loving yeast Malassezia. Malassezia produces lipases (fat-splitting enzymes) that break sebum down into free fatty acids. Those irritate the skin and drive the cycle of itch, redness, and greasy scale. ^23,24

Why it flares

Flares have triggers. They’re predictable once you know what to look for. Cold, dry weather dehydrates the outer skin layer and slows cell turnover, so scale accumulates and yeast byproducts penetrate more easily. Stress increases sebum output and cortisol, which slows repair and amplifies inflammation. Illness or certain medications can shift immune signalling and the scalp microbiome, raising overall reactivity. ²³

Most people learn their own pattern over time — seasonal shifts, stress periods, illness — which makes flares easier to anticipate than prevent. ²³

How SD drives shedding

Scalp inflammation can make hair look and feel thinner even without pattern-type miniaturisation. The mechanism is layered. Inflammation around the follicle opening pushes more hairs into telogen, increasing daily shed counts. Scratching an itchy scalp causes mechanical breakage. Scale buildup at the follicle opening collars emerging hairs, so more release on wash days. And excess oil on the strands makes hair clump and lie flat, so parts look wider than they actually are. ^27,32

Address the inflammation and the Malassezia overgrowth driving it, and shedding settles. Perceived fullness improves. There’s a hypothesis — sometimes called “smouldering alopecia” — that chronic, low-grade follicular inflammation may gradually thin shafts over years through sustained wear. The evidence is limited, but it reinforces the case for managing SD consistently rather than only treating active flares. ^27,32,33

What you’ll see

The scalp gives it away. Redness, greasy yellowish scale, and persistent itch — concentrated along the part line, behind the ears, and at the hairline. Hair feels oilier faster, wash days produce more shedding than feels normal, and the scalp is rarely comfortable for long. ²³

Unlike pattern thinning, the hair itself isn’t miniaturising. Unlike TE, the shedding doesn’t follow a single trigger and resolve. SD-related thinning fluctuates with flare cycles. When the scalp is calm, shedding drops and hair looks fuller. When it flares, everything gets worse at once. ^23,27

Managed, not cured

SD doesn’t have an endpoint. It has a rhythm. The goal is to reduce Malassezia overgrowth, calm inflammation, and extend the time between flares. ^25–29,34

When the scalp is consistently managed, shedding normalises and hair looks and feels fuller between episodes. When maintenance lapses, flares return. Most people find a routine that keeps things stable — see Topical Treatments for what works and how to layer it. ^25–29,34

Antifungal shampoos + topicals ketoconazole, piroctone olamine, ciclopirox, selenium disulfide, zinc pyrithione (where allowed) — lower Malassezia yeast load and downstream irritants via complementary actions:
- - - azoles (ketoconazole) block ergosterol synthesis (14-α-demethylase)
    - piroctone olamine disrupts membranes/iron-dependent metabolism
    - ciclopirox chelates metal ions and inhibits fungal enzymes
    - selenium disulfide is antifungal and slows excessive epidermal turnover
    - zinc pyrithione disrupts membrane function.
  These all result in faster reduction in greasy scale, itch, and redness. Consistent weekly use helps maintain control of flares. Some studies also report fewer shed hairs and improved hair feel.
S^{25–29,32,34,56}
Topical corticosteroids (hydrocortisone) — rapid relief for “hot,” itchy flares. For short-term use only, then step down to antifungal maintenance. Helps redness and tenderness settle within days but may present risk of adverse effects if used longer than directed. M ^30,31
Keratolytics (salicylic acid) — soften and lift compacted scale so antifungals contact the skin more effectively. Also clear follicle openings so emerging hairs pass freely, therefore reducing wash-day shed and fibre breakage while improving scalp comfort. M ²⁷
Barrier & comfort support (ectoin · licochalcone A · peptides · prebiotics) — strengthens the scalp barrier and calms micro-inflammation. Less itch means less scratching (and less scratch-related shedding), a strong and healthy base for new hair growth, and better tolerance of stronger leave-on actives. L

Systemic antifungals (itraconazole, fluconazole) — oral azoles (antifungal drugs) used for severe, widespread, or treatment-resistant SD. They reduce Malassezia by blocking ergosterol synthesis(14-α-demethylase), lowering yeast counts and the irritant by-products that drive inflammation. Relapse is common after stopping—continue topical maintenance; due to potential drug interactions and rare liver effects, dosing is clinician-guided. M ²³
Calcineurin inhibitors (pimecrolimus, tacrolimus; off-label) — non-steroid option for hairline/face and other sensitive sites. Reduces itch and erythema (redness) without risk of skin thinning from prolonged steroid use. M ³⁰
Phototherapy (narrowband UVB/excimer) — short, clinic-dosed light that down-regulates scalp inflammation when shampoos/topicals aren’t enough. Effects are temporary and require multiple sessions; differs from hair-growth phototherapy treatment(red light therapy). L

What maintenance actually looks like

SD responds fast but comes back if you stop too early. The rhythm is: treat the flare aggressively, then step down to a maintenance schedule that keeps it from returning.

During a flare: Antifungal actives (ketoconazole, zinc pyrithione, ciclopirox) 2 to 3 times per week. If inflammation is significant, a short course of topical corticosteroids to calm things down. For stubborn scale, a keratolytic like salicylic acid can improve antifungal penetration. ^26,34
Maintenance: Once symptoms settle (usually 2 to 4 weeks), step down to one or two antifungal washes per week. Some people benefit from alternating actives to avoid building tolerance. This becomes your baseline routine — a consistent plan rather than a reaction to flares. ^26,34

In practice, this means swapping your regular shampoo for an antifungal one a couple of times a week. The mistake most people make is stopping maintenance once their scalp feels normal, then being surprised when it flares again a few weeks later.

If SD and AGA coexist (common), treating the scalp inflammation first can reduce background shedding enough to get a clearer read on what AGA-specific treatments are actually doing.

Reading the signals

Flare triggers to watch for: Winter (dry air, central heating), stress, illness, sleep deprivation, and heavy product use can all tip the balance. If you notice a seasonal pattern, you can pre-empt flares by increasing your antifungal wash frequency before your typical flare window.

Shedding vs flaking: SD-related shedding is driven by inflammation, not follicle miniaturisation. Once inflammation is controlled, shedding normalises. If you’re managing the flaking and itch but still shedding more than expected, check for AGA overlap with your clinician.^23,33

Maintenance is working when: Your scalp feels comfortable, flaking is minimal or absent, and you’re not thinking about it most days. That’s the target state.

The bigger picture

If your SD is affecting how you dress (no dark clothes, hats), how often you socialise, or how much mental energy you spend on it, know that it’s not a hygiene issue. You’re not “dirty”. It’s a chronic condition, and treating it properly tends to resolve both the scalp symptoms and the headspace they were occupying. ²³

Traction · Heat · Chemical Breakage

Traumatic Hair Loss

Thinning and breakage caused by external mechanical, thermal, or chemical stress. Tight styles, high heat, and aggressive chemical processing weaken hair shafts and can inflame the follicle anchor. Usually reversible when the stressor stops. Chronic traction is the exception: ongoing tension can scar follicles permanently. ^36,41,48

Mechanism

Traction (repeated pull) — follicle micro-inflammation, progressing to scarring if sustained.
Heat on damp hair — steam pockets (“bubble hair”) that weaken and snap the shaft.
Chemicals (relaxers, strong bleach) — reduced cystine bonds and increased porosity, leaving brittle, breakage-prone fibres.

Early changes are often reversible once the stress stops. ^{36,41,48,52,53}

Typical Pattern

Thinning and breakage concentrated at tension points (temples, frontal hairline, part line). The fringe sign (preserved short hairs at the hairline) is a traction indicator. Heat and chemical damage shows as mid-shaft breakage, split ends, dullness, and loss of volume. ^{36,48,52,54,53}

Common When

Tight or repetitive styles (braids, weaves, ponytails, extensions), frequent relaxers, bleach, or perms, and regular hot-tool use on unprotected or damp hair. High-manipulation detangling and aggressive brushing increase risk. ^{36,41,48,52,53}

What to expect

Recovery depends entirely on when the stressor stops. Early intervention is fully reversible. Chronic traction can cross into permanent scarring.

Stop the stressor

Remove tension, reduce heat, pause chemical processing. This is the treatment.

Month 1–3

Breakage slows. Existing damage is visible but no new damage forming.

Month 3–6

New growth fills in. Stronger shafts replace broken or miniaturised hairs.

Month 6–12

Visible recovery. Length and density rebuild. Full cycle takes ~12 months.

If no regrowth appears after 6 to 12 months of eliminating the stressor, scarring may have occurred. A clinician can assess with dermoscopy.

The Science: Two kinds of damage

Traumatic hair loss works through two distinct targets. Traction damages the follicle itself — the anchor, the socket, the stem-cell region. Heat and chemicals damage the strand — the fibre that’s already grown out. ^36,41,52,53

The distinction matters because the consequences are different. Follicle damage can become permanent if it scars. Strand damage can’t — the follicle keeps producing new hair, it’s just that the hair keeps breaking before it reaches a useful length. Most people are dealing with some combination of both. ^36,41,52,53

How tension damages follicles

Each hair sits in a cushioned socket anchored by connective tissue and a small muscle (the arrector pili) that hooks in at the bulge, a stem-cell-rich band on the outer root sheath. When hairstyles pull tight, that anchor absorbs the load. Repeated strain triggers micro-inflammation at the follicle opening. ^36,41

Remove the tension and the inflammation resolves. Continue it and the repair response lays down excess collagen, stiffening the socket. This is fibrosis — the early stage of scarring. ^36,41

How heat and chemicals damage strands

Heat and chemical damage happen to the fibre, not the follicle. The follicle keeps working. The problem is that what it produces keeps breaking.

Heat applied to damp hair flashes residual water into steam, creating air-filled pockets in the cortex known as bubble hair. These collapse the keratin scaffold and leave weak points that snap. High heat also lifts the cuticle, increasing friction — so strands catch and break more easily with brushing and styling. ⁵²

Chemical relaxers break and rearrange keratin’s cystine cross-links, reducing elasticity and tensile strength with each treatment. Bleaching oxidises both melanin and keratin, lifting the cuticle and stripping protective lipids. The result is higher porosity, lower elasticity, and fibres that snap and split more easily with each service. ⁵³

What you’ll see

Traction shows up at the points of tension. Thinning at the temples, along the hairline, or at the part line where styles pull tightest. The fringe sign — a thin line of fine, wispy hairs at the very edge of the hairline, surviving while the hair behind them thins — is a classic indicator. The scalp in affected areas may look slightly red or tender. ^36,48,54

Heat and chemical damage shows up in the strands themselves. Mid-shaft breakage, split ends, rough texture, dullness, and hair that won’t hold length no matter how long you go between trims. Wet hair may stretch and not spring back, or snap with minimal force. The scalp itself usually looks fine. ^52,53

The scarring threshold

Traction damage exists on a spectrum. Early on, the inflammation is reversible. Stop the tension and follicles recover over subsequent growth cycles. ^36,41

Past a certain point, the repair response shifts from inflammation to fibrosis. Collagen replaces the follicle’s anchor. The socket stiffens, the stem-cell region gets walled off, and the follicle shuts down permanently. This is scarring alopecia. The skin in these areas may look smooth and shiny, with no visible follicle openings. ^36,41

There’s no clean line between reversible and permanent. It depends on how tight, how long, and how often. But the progression only goes one direction. Early intervention is always better than later. ^36,41

How recovery works

For tension damage: reduce the mechanical load. Once inflammation settles, non-scarred follicles re-enter growth over subsequent cycles. Where scarring has already formed, those follicles are unlikely to recover. ^36,41

For strand damage: the goal is reducing the rate of breakage so new growth can retain its length. Lower heat settings, fewer chemical services, gentler handling, and products that reduce friction and support the cuticle all help. The follicles are fine — it’s about protecting what they produce. See Topical Treatments for specifics. ^52,53

Scalp Treatments

Minoxidil (topical) — helps “resting” follicles restart growth. In early, non-scarring traction it can add visible fullness with steady use over a few months. It can’t reverse scarring—low-tension styling is the main fix. L ^6,36,41
Antifungal topicals (when buildup/itch is present): ketoconazole · piroctone olamine — tight styles can trap oils and product at follicle openings, fostering dandruff/folliculitis that makes traction feel worse. Antifungal shampoos or leave-ons cut yeast and debris, ease itch/redness, and keep the scalp more comfortable while you shift to low-tension habits. They won’t reverse traction damage. L ^25–27,32
Salicylic acid — a gentle keratolytic that loosens compacted flakes/product at the follicle opening. Clearing this debris can reduce snagging on fragile hairs and help leave-ons reach the scalp. L ^27,36
Antioxidants (ginsenosides · polyphenols) — help neutralise free radicals created by heat and chemical services that roughen the cuticle and weaken keratin. Used before/after styling and around chemical treatments, they can keep fibres smoother and less prone to snap, while calming the scalp to support a healthier growth environment. L ^14,42,43
Scalp barrier + microenvironment support (ectoin · licochalcone A · prebiotics · peptides) — strengthens the skin’s barrier and calms irritation, so the scalp is less reactive to tension, heat, and products. Better hydration and a steadier microbiome mean less itch, improved tolerance of leave-ons, and a cleaner path for emerging hairs—supporting retention while habits change. L

Hair (Shaft) Treatments

Cease traction/insults — switch to low-tension styles, reduce heat, and space chemical services; this is the core treatment at any stage. S ^36,41,48
Friction + Cuticle Control (silicones · cationic conditioners · acidifying rinses pH 4–5) — lowers combing force, improves slip, and keeps the cuticle flatter to reduce snagging during detangling/heat passes; helps limit snap-offs in day-to-day handling. L ⁵²
Structural support (bond-repair systems · film formers · hydrolyzed proteins) — can make damaged hair behave more like undamaged hair—for a while. These create micro-films or short-lived cross-links that smooth rough spots and add temporary strength, so hair snaps and splits less. They don’t undo heat/chemical damage or permanently rebuild native bonds. Effects wash or wear out over time (bond-patch is technically more accurate than bond-repair) so reapply between washes and keep heat/tension low. L ⁴²
Heat/Stress Guards (heat protectants · antioxidants · amino acids) — buffers temperature spikes and oxidative by-products from tools/chemicals/environment; helps protect fibre integrity during styling and colouring. L ^52,53

Intralesional corticosteroids (triamcinolone injections placed into the red/tender edge of a patch) — calm the local inflammatory response at the follicle anchor so surviving follicles can cycle back to growth. Used as an add-on for early or inflamed traction alopecia, always alongside stopping traction. Typically given every 4–6 weeks for a few sessions. Not helpful once smooth, shiny skin signals established scarring. M ⁵⁵
Surgery/camouflage — in established scarring, consider wigs or selective transplantation once stable. L ^36,41

Building your approach

The treatment is removing what’s causing the damage. For traction, that means loosening styles. For heat damage, reducing temperature and frequency. For chemical damage, spacing services further apart. In each case, removing the stressor is the primary intervention — and it’s often enough for full recovery if scarring hasn’t set in. ^36,41

If dermoscopy shows early scarring (loss of follicular openings, perifollicular fibrosis), a clinician may add anti-inflammatory treatment to slow the process while the stressor is being removed. ^36,41,48

Protecting what’s growing back

New growth is fragile. Reducing breakage lets it reach a visible length rather than snapping off. A few habits that help: use a leave-in conditioner or detangling spray before brushing, work in small sections from ends to roots, lower your heat settings, and choose styles that spread tension evenly. ^52,53

These don’t need to be all-or-nothing changes. Going from a very tight style to a moderately loose one, or from weekly heat styling to fortnightly, can be enough.

Reading the signals

Recovery: Breakage slows within 1 to 3 months. New growth fills in over 3 to 6 months. Visible density rebuilds over 6 to 12 months.
Scarring warning signs: Red or pink halos around hairs, scale or sleeves at the hair base, persistent tenderness after loosening styles, shiny patches with fewer visible follicle openings, tufting (several hairs from one pore), or areas that don’t regrow after 3 to 6 months of reduced tension. ^36,41,48

If any scarring signs appear, see a dermatologist promptly. Early intervention is the difference between reversible and permanent.

The bigger picture

Hair is personal. Colouring, straightening, extensions, protective styles, heat styling — the ways people shape their hair are tied to identity, culture, and self-expression. “Just stop doing that” isn’t useful advice when the practice matters to you. A good clinician or stylist will work with your goals to find a routine and style you love that your scalp can also sustain. ^36,48

Medical Factors

Iron · Thyroid · Medications

Low iron (ferritin), thyroid imbalance, and certain medications can each trigger a temporary, diffuse shed across the scalp. The pattern is consistent: more follicles enter rest together, shedding peaks, and density dips. Identify and address the underlying driver, and hair typically rebuilds over normal cycle timelines. ^68–72

Mechanism

Low ferritin limits iron supply to matrix cells, shortening anagen and shifting hairs into telogen. ^68,71,85 Thyroid hormones regulate anagen length and telogen entry; both hypo- and hyperthyroid states can synchronise a telogen wave. ^70,73 Some medications transiently shift the cycle, with shedding typically appearing 6 to 12 weeks after a start, stop, or dose change. A smaller number cause rapid anagen effluvium (direct matrix toxicity). ⁷²

Typical Pattern

Diffuse shedding from all over the scalp. Temporary and non-scarring: scalp skin and follicle openings look normal, with no marked redness or thick scale. A hair-pull test is often positive during active shedding. This pattern can unmask or amplify underlying androgenetic thinning. ^69,71,86

Common When

Onset often aligns with low ferritin on labs (with or without anaemia), abnormal TSH, or a recent medication change: hormonal agents, anticoagulants, SSRIs/SNRIs, β-blockers, oral retinoids, or anticonvulsants/mood stabilisers. Shedding typically appears 6 to 12 weeks after the trigger. ^68,70,72,84

What to expect

Recovery is tied to resolving the underlying driver. Once labs normalise or the medication is adjusted, the hair cycle resets on its own schedule.

Identify trigger

Lab work confirms low ferritin, abnormal TSH, or medication link.

Correct

Supplement, dose adjust, or switch medication. Labs recheck at 6 to 8 weeks.

Month 2–4

Shedding begins to slow as follicles re-enter growth. Lag is normal.

Month 6–9

Visible density returning. New hairs reaching noticeable length.

If density doesn’t recover after labs normalise, underlying pattern thinning (AGA) may have been unmasked. Worth discussing with your clinician.

The Science: Why medical factors cause shedding

Iron deficiency, thyroid dysfunction, and medication changes all cause hair loss through the same basic mechanism: they push a larger-than-normal share of follicles out of growth and into rest. The result is diffuse shedding across the scalp, typically peaking 2 to 3 months after the disruption. No follicles are damaged. This is the same telogen shift described in the Excess Shedding section, but here the trigger is a specific, identifiable medical driver. ^68,70,72

The common drivers

Iron deficiency. Ferritin reflects how much iron is available to the follicle’s fast-dividing matrix cells. When stores drop, matrix proliferation slows, anagen shortens, and more follicles shift into telogen. This can drive diffuse shedding even without full anaemia. Ferritin is best interpreted alongside haemoglobin, MCV, and other iron indices. If inflammation is suspected, CRP helps clarify the picture. ^68,85

Thyroid dysfunction. Follicles have thyroid hormone receptors and are directly responsive to T3/T4 levels. Hypothyroidism slows matrix turnover and increases the telogen fraction — hair often becomes drier and coarser. Hyperthyroidism accelerates cycling with premature release — hair may feel finer with an increased daily shed. Testing starts with TSH. If results are abnormal, your clinician may add free T4, free T3, and thyroid antibodies. ^70,73

Medication changes. Certain drugs shift follicles into telogen as a side effect, typically peaking 6 to 12 weeks after a start, stop, or dose change. Common associations include hormonal agents (contraception, HRT), SSRIs/SNRIs, β-blockers, anticoagulants, oral retinoids, anticonvulsants (valproate, lithium), and thyroid dose adjustments during titration. If the timing of a shedding surge lines up with a medication change, share that timeline with your clinician. Do not adjust medications on your own. ⁷²

What you’ll see

The picture is the same as telogen effluvium: more hairs on your pillow, brush, and in the shower, spread evenly across the scalp. The scalp looks healthy. No patches, no scarring. The difference is that medically driven shedding won’t fully resolve on its own. It needs the underlying driver corrected. ^69,71,86

Anagen effluvium

There’s a separate pattern worth knowing. Most medical shedding is a telogen shift — follicles enter rest early and shed weeks later. Anagen effluvium is different. Cytotoxic chemotherapy and certain other agents directly poison the rapidly dividing matrix cells, causing actively growing hairs to break or fall within 1 to 3 weeks. The loss is fast, often severe, and clearly linked to treatment. ⁷²

Because the damage targets the hair shaft rather than the follicle’s stem cells, regrowth typically begins once treatment ends. The timeline and texture of regrowth vary, but the follicles themselves survive. ⁷²

How recovery works

Recovery follows a specific sequence. Labs normalise first. Your blood work may look perfect while your hair is still shedding — that’s normal. The follicles that entered telogen during the deficiency or imbalance are still working through their resting phase. ^68,70,72

Shedding slows next, typically 2 to 4 months after the driver is corrected. Then density recovers last, as new hairs need time to grow to a visible length. For most people, that’s the 6 to 9 month mark, sometimes longer. ^69,71

If labs normalise but density doesn’t recover, consider that the medical trigger may have unmasked pre-existing pattern thinning (AGA). This overlap is common and worth investigating with your clinician. ^69,71

Minoxidil (topical) — prolongs anagen via K⁺-channel opening and ↑VEGF, helping coverage rebound while iron/thyroid/medication drivers are corrected. M ^6,10,71
Caffeine — adjunct. Lab data suggest anti-androgenic/↑cAMP effects; small human studies show modest support for shedding/density perception during the correction phase. L ¹³
Adenosine — A_2A signalling (↑FGF-7/KGF, ↑VEGF) with calibre/anagen gains in AGA trials; useful as a bridge while ferritin/TSH normalise. L ¹²
Keratolytics (salicylic acid) — lift compact scale/product to improve leave-on contact and reduce mechanical tug on emerging hairs; go gentle on reactive scalps. L
Antioxidants (polyphenols · tocopherol nicotinate · ginsenosides) — temper oxidative stress and micro-inflammation and support microcirculation (tocopherol nicotinate); some(ginsenosides) also up-regulate VEGF. Creates a more permissive setting for regrowth while the systemic driver is addressed. L ^14,43
Barrier + microenvironment support (ectoin · prebiotics · peptides · gentle cleansing) — keeps the scalp comfortable and tolerant of actives during recovery, supporting consistency and visible retention of new growth. L

Iron status — ask your doctor for the right labs ^68,85
- What to request: Ferritin plus a CBC (haemoglobin/haematocrit, MCV). Your clinician may add an iron panel (serum iron, transferrin saturation, TIBC) and CRP if inflammation is suspected.
- Why it matters: Ferritin reflects iron available to fast-dividing matrix cells; when stores are low, anagen shortens and more hairs sit in telogen (diffuse shed).
- Good questions: “If ferritin is low or borderline for me, what could be driving it (diet, postpartum blood loss, heavy periods), how should we replete, and when should we re-check?”
Thyroid check — confirm your levels are in range ⁷⁰
- What to request: Start with TSH; if it’s off(or symptoms fit), add free T4 (± free T3). If autoimmune thyroid disease is possible, ask about TPO antibodies (Hashimoto’s/postpartum thyroiditis) or TRAb/TSI (Graves).
- Why it matters: Follicles respond to thyroid hormones; hypo- or hyperthyroidism can synchronise a telogen shed. Returning labs to your usual range typically lets cycles resettle over weeks–months (a brief shed can happen during dose adjustments).
- Good questions: “How often should we monitor? What hair timeline should I expect once levels stabilise? When do we re-test if shedding continues?”
Medicines — map the timeline with your clinician ⁷²
- Pattern to know: Telogen effluvium often shows up ~6–12 weeks after a start/stop/dose change.
- Bring a list of recent changes. Classes that can be associated include:
  - Hormonal agents — contraception or HRT shifts (more androgenic progestins can unmask pattern-type thinning).
  - Antidepressants — SSRIs/SNRIs, bupropion.
  - β-blockers — including labetalol.
  - Anticoagulants — heparins, warfarin.
  - Oral retinoids / high vitamin A.
  - Anticonvulsants / mood stabilisers — valproate, lithium.
  - Thyroid therapy titration — transient shifts while doses are being adjusted.
- Good questions: “Given my history, which meds are most likely? Are there alternatives or timing tweaks to consider? How will we track hair response if we change something?” (Don’t alter prescriptions on your own.)
Nutrition & weight change — sanity-check the basics ⁶⁹
- What to review: Recent rapid weight loss, low-energy/low-protein patterns, or micronutrient gaps.
- Why it matters: Energy/protein shortfalls can push follicles out of growth(anagen) and toward telogen.
- Good questions: “What’s a realistic stabilisation plan (energy, protein, iron-rich foods)? Do I need dietitian support or any labs beyond iron in my case?”

Building your approach

Medical hair loss is about correcting the upstream driver. Once the underlying condition is properly managed, the hair cycle will respond over time. The first step is identifying what’s actually behind the shed — which usually means blood work, a medication review, and a look at what’s changed in the past 6 to 12 months. ^68,69

Iron deficiency: One of the most common and most under-tested contributors. Supplement to raise ferritin (your clinician will set a target — often above 40 to 70 µg/L for hair). Recheck labs at 8 to 12 weeks. Shedding typically slows before density visibly recovers, because the new hairs need time to reach noticeable length. ^68,71
Thyroid dysfunction: Both underactive and overactive thyroid can trigger diffuse shedding. TSH/FT4 are typically rechecked 6 to 8 weeks after any dose change. Hair improvements trail lab normalisation by another full growth cycle — expect months, not weeks. ^70,73
Medication-related: If a medication is the suspected trigger, the decision to switch or adjust involves your prescribing clinician. Don’t self-adjust prescriptions. Many medications can shift more follicles into telogen (anticoagulants, SSRIs/SNRIs, β-blockers, oral retinoids, lithium, valproate). Shedding is usually temporary and self-correcting once the body adapts to the medicine. ^72,84
Other drivers: Rapid weight loss, restrictive diets, PCOS, chronic inflammation, and poorly controlled diabetes can all affect the hair cycle. Worth raising if the more obvious causes have been ruled out. ⁶⁹

More than one of these can be active at the same time. If treatment for one driver doesn’t fully resolve the shedding, revisit the list rather than assuming it’s not working.

Reading the signals

The timeline of medical hair loss has a specific lag pattern:

Labs normalise first. Your blood work may look perfect while your hair is still shedding. This is normal. The follicles that entered telogen during the deficiency or imbalance are still working through their resting phase.

Then shedding slows. Typically 2 to 4 months after the underlying driver is corrected. The rate of new hairs entering telogen drops, so fewer hairs are falling at any given time.

Density recovers last. New hairs need time to grow to a visible length. This is the 6 to 9 month mark for most people, sometimes longer.

If labs normalise but density doesn’t recover, consider that the medical trigger may have unmasked pre-existing AGA. This overlap is common and worth investigating with dermoscopy. ^69,71

Working with your clinician

Keep a simple timeline of relevant events: illness, surgery, major stress, weight changes, and any medication starts, stops, or dose changes. Hair often reacts 6 to 12 weeks later. Matching today’s shedding to what happened a couple of months back gives your clinician useful data and saves appointment time. ⁷²

For iron: Ask for ferritin specifically, not just a CBC. Ferritin can be low enough to affect hair while your haemoglobin is technically normal. ^68,71
For thyroid: If you’re on levothyroxine and your hair hasn’t improved despite normal TSH, ask about checking FT3 as well. Some people convert T4 to T3 less efficiently, and hair follicles are sensitive to T3 levels. ^70,73
For medications: Bring a list of everything you take, including supplements and contraception. Ask specifically: “Could any of these be contributing to my shedding?” Clinicians don’t always volunteer this unless asked. ^72,84

The bigger picture

Medical hair loss can feel doubly frustrating: you’re already managing a health condition, and now your hair is a casualty of it. The lag between “labs look normal” and “hair looks normal” is where most of the distress sits. You’ve done everything right and the mirror hasn’t caught up yet.

That lag is real and predictable. It doesn’t mean the treatment isn’t working. But knowing that intellectually doesn’t always stop the worry. If you’re finding it hard to trust the process — checking the drain obsessively, taking daily photos, catastrophising — be honest with yourself about whether the monitoring has become its own source of stress. Monthly photos in consistent lighting are useful. Daily scrutiny usually isn’t. ⁷¹

References

Return to → 01 Genetic/Pattern Thinning

5 Szendzielorz, E., & Spiewak, R. (2025). Adenosine as an Active Ingredient in Topical Preparations Against Hair Loss: A Systematic Review and Meta-Analysis of Published Clinical Trials. Biomolecules, 15(8), 1093. DOI: 10.3390/biom15081093 Adenosine as an active ingredient in topical preparations against hair loss: a systematic review.
6 Elise A. Olsen, Rodney Sinclair, Maria Hordinsky, Natasha A. Mesinkovska, Neil Sadick, Jerry Shapiro, Wilma Bergfeld, Summation and recommendations for the safe and effective use of topical and oral minoxidil, Journal of the American Academy of Dermatology, Volume 93, Issue 2, 2025, Pages 457-465, ISSN 0190-9622, DOI: 10.1016/j.jaad.2025.04.016. Summation and recommendations for the safe and effective use of topical and oral minoxidil.
8 Rathnayake, D., & Sinclair, R. (2010). Male androgenetic alopecia. Expert Opinion on Pharmacotherapy, 11(8), 1295–1304. DOI: 10.1517/14656561003752730 Male androgenetic alopecia.
9 Trüeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37(8–9):981–990. DOI: 10.1016/S0531-5565(02)00093-1 Molecular mechanisms of androgenetic alopecia.
10 Gupta AK, Charrette A. Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia. Skinmed. 2015 May-Jun;13(3):185-9. PMID: 26380504. Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia.
11 Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia: A Systematic Review. Arch Dermatol. 2010;146(10):1141–1150. doi: 10.1001/archdermatol.2010.256 Finasteride therapy for androgenetic alopecia: systematic review.
12 OURA, H., IINO, M., NAKAZAWA, Y., TAJIMA, M., IDETA, R., Nakaya, Y., ARASE, S. and KISHIMOTO, J. (2008), Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: A pilot, double-blind, randomized, placebo-controlled trial. The Journal of Dermatology, 35: 763-767. DOI: 10.1111/j.1346-8138.2008.00564.x Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: A pilot, double-blind, randomized, placebo-controlled trial.
13 Szendzielorz, E., & Spiewak, R. (2025). Caffeine as an Active Ingredient in Cosmetic Preparations Against Hair Loss: A Systematic Review of Available Clinical Evidence. Healthcare, 13(4), 395. DOI: 10.3390/healthcare13040395 Caffeine as an Active Ingredient in Cosmetic Preparations Against Hair Loss: A Systematic Review of Available Clinical Evidence.
14 M.G. Davis, M.P. Piliang, W.F. Bergfeld, T.L. Caterino, B.K. Fisher, J.P. Sacha, G.J. Carr, L.T. Moulton, D.J. Whittenbarger, J.R. Schwartz, Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial. Int. J. Cosmet. Sci. 43, S14–S25(2021). DOI: 10.1111/ics.12734 Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial.
15 Kumar MK, Inamadar AC, Palit A. A Randomized Controlled, Single-Observer Blinded Study to Determine the Efficacy of Topical Minoxidil plus Microneedling versus Topical Minoxidil Alone in the Treatment of Androgenetic Alopecia. J Cutan Aesthet Surg. 2018 Oct-Dec;11(4):211-216. doi: 10.4103/JCAS.JCAS_130_17. PMID: 30886475; PMCID: PMC6371730. A Randomized Controlled, Single-Observer Blinded Study to Determine the Efficacy of Topical Minoxidil plus Microneedling versus Topical Minoxidil Alone in the Treatment of Androgenetic Alopecia.
35 Qi J, Garza LA. An overview of alopecias. Cold Spring Harb Perspect Med. 2014 Mar 1;4(3):a013615. doi: 10.1101/cshperspect.a013615. PMID: 24591533; PMCID: PMC3935391. An overview of alopecias.
37 Australasian College of Dermatologists. (2023, August). Androgenetic alopecia (in men). Androgenetic alopecia (in men).
43 Shin DH, Cha YJ, Yang KE, et al. Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles. Phytotherapy Research : PTR. 2014 Jul;28(7):1088-1095. DOI: 10.1002/ptr.5101. PMID: 24375856. Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles.
44 Fischer TW, Hipler UC, Elsner P. Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro. Int J Dermatol. 2007 Jan;46(1):27-35. doi: 10.1111/j.1365-4632.2007.03119.x. PMID: 17214716. Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro.
46 Babadjouni A, Reddy M, Zhang R, et al. Melatonin and the human hair follicle. J Drugs Dermatol. 2023;22(3):260-264. doi:10.36849/JDD.6921 Melatonin and the human hair follicle.
47 Sawaya ME, Price VH. Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3):296–300. doi:10.1111/1523-1747.ep12335779. Different enzyme/receptor levels in AGA follicles.
49 Menopause and hair loss in women: Exploring the hormonal transition. Gupta, Aditya K. et al. Maturitas, Volume 198, 108378. doi: 10.1016/j.maturitas.2025.108378. Menopause and hair loss in women: Exploring the hormonal transition.
50 Chen X, Xiang H, Yang M. Topical cetirizine for treating androgenetic alopecia: A systematic review. J Cosmet Dermatol. 2022. doi: 10.1111/jocd.15309. PMID: 35976065. Topical cetirizine for treating androgenetic alopecia: a systematic review.
51 El-Komy MH, Samir N, Shaker OG. The efficacy of topical cetirizine using microneedling in androgenetic alopecia male patients. Arch Dermatol Res. 2025;317:539. PMID: 40167621. The efficacy of topical cetirizine using microneedling in androgenetic alopecia male patients.
63 Liu KH, Liu D, Chen YT, Chin SY. Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a system review and meta-analysis of randomized controlled trials. Lasers Med Sci. 2019 Aug;34(6):1063-1069. doi: 10.1007/s10103-019-02723-6. Epub 2019 Jan 31. PMID: 30706177. Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a system review and meta-analysis of randomized controlled trials.
64 Zhang X, Ji Y, Zhou M, Zhou X, Xie Y, Zeng X, Shao F, Zhang C. Platelet-Rich Plasma for Androgenetic Alopecia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Cutan Med Surg. 2023 Sep-Oct;27(5):504-508. doi: 10.1177/12034754231191461. Epub 2023 Aug 2. PMID: 37533146. Platelet-Rich Plasma for Androgenetic Alopecia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
65 Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J Am Acad Dermatol. 2021 Mar;84(3):737-746. doi: 10.1016/j.jaad.2020.06.1009. Epub 2020 Jul 2. PMID: 32622136. Oral minoxidil treatment for hair loss: A review of efficacy and safety.
66 Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Mar 1;158(3):266-274. doi: 10.1001/jamadermatol.2021.5743. PMID: 35107565; PMCID: PMC8811710. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis.
69 Harfmann KL, Bechtel MA. Hair loss in women. Clin Obstet Gynecol. 2015 Mar;58(1):185-99. doi: 10.1097/GRF.0000000000000081. PMID: 25517757. Hair loss in women.
74 Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004 Feb;150(2):341-5. doi: 10.1111/j.1365-2133.2004.05685.x. PMID: 14996107. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial.
75 Takahashi T, Kamimura A, Kusano K, et al. Investigation of topical application of procyanidin B-2 from apple to identify its potential use as a hair-growing agent. Phytomedicine. 2000;7(6):529–536. doi:10.1016/S0944-7113(00)80040-9. Investigation of topical application of procyanidin B-2 from apple to identify its potential use as a hair-growing agent.
76 Takahashi T, Kamimura A, Kagoura M, et al. A randomized double-blind, placebo-controlled trial of 0.7% procyanidin oligomers from apples for the treatment of male pattern baldness. J Cosmet Dermatol. 2005;4(4):245–249. doi:10.1111/j.1473-2165.2005.00199.x. A randomized double-blind, placebo-controlled trial of 0.7% procyanidin oligomers from apples for the treatment of male pattern baldness.
77 Panchaprateep R, Lueangarun S, Jaruchanapongtorn S, et al. An herbal extract combination (biochanin A, acetyl tetrapeptide-3, and ginseng extracts) versus 3% minoxidil solution for the treatment of androgenetic alopecia: A 24-week, prospective, randomized, triple-blind, controlled trial. J Clin Aesthet Dermatol. 2020 Oct;13(10):32–37. An Herbal Extract Combination (Biochanin A, Acetyl tetrapeptide-3, and Ginseng Extracts) versus 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A 24-week, Prospective, Randomized, Triple-blind, Controlled Trial
78 Wu C-J, Yang C-Y, So PB, et al. Safety Profile and Efficacy of Biosea® Revive Serum for Hair Growth Through In Vitro Assessment and Clinical Evaluation. Cosmetics. 2025;12(4):139. doi:10.3390/cosmetics12040139. Safety Profile and Efficacy of Biosea® Revive Serum for Hair Growth Through In Vitro Assessment and Clinical Evaluation
79 Shin HS, Won CH, Lee SH, Kwon OS, Kim KH, Eun HC. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. Am J Clin Dermatol. 2007;8(5):285–290. doi:10.2165/00128071-200708050-00003. Efficacy of 5% Minoxidil versus Combined 5% Minoxidil and 0.01% Tretinoin for Male Pattern Hair Loss.
80 Ferry JJ, Forbes KK, VanderLugt JT, Szpunar GJ. Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution. Clin Pharmacol Ther. 1990;47(4):439–446. PMID: 2328551. Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution.
81 Yoo HG, Chang IY, Pyo HK, Kang YJ, Lee SH, Kwon OS, Cho KH, Eun HC, Kim KH. The additive effects of minoxidil and retinol on human hair growth in vitro. Biol Pharm Bull. 2007;30(1):21–26. PMID: 17202653. The additive effects of minoxidil and retinol on human hair growth in vitro.
82 Kwon OS, Pyo HK, Oh YJ, Han JH, Lee SR, Chung JH, Eun HC, Kim KH. Promotive effect of minoxidil combined with all-trans retinoic acid (tretinoin) on human hair growth in vitro. J Korean Med Sci. 2007;22(2):283–289. doi:10.3346/jkms.2007.22.2.283. Promotive Effect of Minoxidil Combined with All-trans Retinoic Acid (tretinoin) on Human Hair Growth in Vitro.
83 Sharma A, Goren A, Dhurat R, Agrawal S, Sinclair R, Trüeb RM, Vañó-Galván S, Chen G, Tan Y, Kovacevic M, Situm M, McCoy J. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019 May;32(3):e12915. doi: 10.1111/dth.12915. Epub 2019 Apr 23. PMID: 30974011. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes.
87 Rosette C, Rosette N, Mazzetti A, et al. Cortexolone 17α-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol. 2019;18(2):197–201. PMID: 30811143. Cortexolone 17α-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro.
88 Cosmo Pharmaceuticals N.V. Phase III topline results from Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) for clascoterone 5% solution in male androgenetic alopecia. Published December 3, 2025. Phase III trials: clascoterone 5% solution in male androgenetic alopecia (Scalp 2).
89 Mostafa DH, Samadi A, Niknam S, Nasrollahi SA, Guishard A, Firooz A. Efficacy of cetirizine 1% versus minoxidil 5% topical solution in the treatment of male alopecia: a randomized, single-blind controlled study. J Pharm Pharm Sci. 2021;24:191–199. PMID: 33909554. Efficacy of cetirizine 1% versus minoxidil 5% topical solution in the treatment of male alopecia.

Return to → 02 Excess Shedding

1 Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002 Jul;27(5):389-395. doi: 10.1046/j.1365-2230.2002.01080.x. PMID: 12190639. Telogen effluvium
2 Hughes EC, Syed HA, Saleh D. Telogen Effluvium. [Updated 2024 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: Telogen effluvium.
3 Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. J Am Acad Dermatol. 1996;35(6):899–906. DOI: 10.1016/S0190-9622(96)90113-9 Chronic telogen effluvium: increased scalp hair shedding in middle-aged women.
4 Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–194. DOI: 10.1111/j.1365-2133.2004.05785.x Minoxidil: mechanisms of action on hair growth.
5 Szendzielorz, E., & Spiewak, R. (2025). Adenosine as an Active Ingredient in Topical Preparations Against Hair Loss: A Systematic Review and Meta-Analysis of Published Clinical Trials. Biomolecules, 15(8), 1093. DOI: 10.3390/biom15081093 Adenosine as an active ingredient in topical preparations against hair loss: a systematic review.
6 Elise A. Olsen, Rodney Sinclair, Maria Hordinsky, Natasha A. Mesinkovska, Neil Sadick, Jerry Shapiro, Wilma Bergfeld, Summation and recommendations for the safe and effective use of topical and oral minoxidil, Journal of the American Academy of Dermatology, Volume 93, Issue 2, 2025, Pages 457-465, ISSN 0190-9622, DOI: 10.1016/j.jaad.2025.04.016. Summation and recommendations for the safe and effective use of topical and oral minoxidil.
7 Malkud S. Telogen effluvium: a review. Journal of Clinical and Diagnostic Research. 2015;9(9):WE01–WE03. DOI: 10.7860/JCDR/2015/15219.6492 Telogen effluvium: a review.
10 Gupta AK, Charrette A. Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia. Skinmed. 2015 May-Jun;13(3):185-9. PMID: 26380504. Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia.
12 OURA, H., IINO, M., NAKAZAWA, Y., TAJIMA, M., IDETA, R., Nakaya, Y., ARASE, S. and KISHIMOTO, J. (2008), Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: A pilot, double-blind, randomized, placebo-controlled trial. The Journal of Dermatology, 35: 763-767. DOI: 10.1111/j.1346-8138.2008.00564.x Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: A pilot, double-blind, randomized, placebo-controlled trial.
13 Szendzielorz, E., & Spiewak, R. (2025). Caffeine as an Active Ingredient in Cosmetic Preparations Against Hair Loss: A Systematic Review of Available Clinical Evidence. Healthcare, 13(4), 395. DOI: 10.3390/healthcare13040395 Caffeine as an Active Ingredient in Cosmetic Preparations Against Hair Loss: A Systematic Review of Available Clinical Evidence.
14 M.G. Davis, M.P. Piliang, W.F. Bergfeld, T.L. Caterino, B.K. Fisher, J.P. Sacha, G.J. Carr, L.T. Moulton, D.J. Whittenbarger, J.R. Schwartz, Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial. Int. J. Cosmet. Sci. 43, S14–S25(2021). DOI: 10.1111/ics.12734 Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial.
27 Waldroup W, Scheinfeld N. Medicated shampoos for the treatment of seborrheic dermatitis. Journal of Drugs in Dermatology : JDD. 2008 Jul;7(7):699-703. PMID: 18664167. Medicated shampoos for the treatment of seborrheic dermatitis.
40 Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000Res. 2017 Sep 6;6:1650. doi: 10.12688/f1000research.11775.1. PMID: 29167734; PMCID: PMC5676194. Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study.
43 Shin DH, Cha YJ, Yang KE, et al. Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles. Phytotherapy Research : PTR. 2014 Jul;28(7):1088-1095. DOI: 10.1002/ptr.5101. PMID: 24375856. Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles.
44 Fischer TW, Hipler UC, Elsner P. Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro. Int J Dermatol. 2007 Jan;46(1):27-35. doi: 10.1111/j.1365-4632.2007.03119.x. PMID: 17214716. Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro.
46 Babadjouni A, Reddy M, Zhang R, et al. Melatonin and the human hair follicle. J Drugs Dermatol. 2023;22(3):260-264. doi:10.36849/JDD.6921 Melatonin and the human hair follicle.
74 Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004 Feb;150(2):341-5. doi: 10.1111/j.1365-2133.2004.05685.x. PMID: 14996107. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial.

Return to → 03 Postpartum Shedding

2 Hughes EC, Syed HA, Saleh D. Telogen Effluvium. [Updated 2024 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: Telogen effluvium.
5 Szendzielorz, E., & Spiewak, R. (2025). Adenosine as an Active Ingredient in Topical Preparations Against Hair Loss: A Systematic Review and Meta-Analysis of Published Clinical Trials. Biomolecules, 15(8), 1093. DOI: 10.3390/biom15081093 Adenosine as an active ingredient in topical preparations against hair loss: a systematic review.
6 Elise A. Olsen, Rodney Sinclair, Maria Hordinsky, Natasha A. Mesinkovska, Neil Sadick, Jerry Shapiro, Wilma Bergfeld, Summation and recommendations for the safe and effective use of topical and oral minoxidil, Journal of the American Academy of Dermatology, Volume 93, Issue 2, 2025, Pages 457-465, ISSN 0190-9622, DOI: 10.1016/j.jaad.2025.04.016. Summation and recommendations for the safe and effective use of topical and oral minoxidil.
10 Gupta AK, Charrette A. Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia. Skinmed. 2015 May-Jun;13(3):185-9. PMID: 26380504. Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia.
12 OURA, H., IINO, M., NAKAZAWA, Y., TAJIMA, M., IDETA, R., Nakaya, Y., ARASE, S. and KISHIMOTO, J. (2008), Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: A pilot, double-blind, randomized, placebo-controlled trial. The Journal of Dermatology, 35: 763-767. DOI: 10.1111/j.1346-8138.2008.00564.x Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: A pilot, double-blind, randomized, placebo-controlled trial.
13 Szendzielorz, E., & Spiewak, R. (2025). Caffeine as an Active Ingredient in Cosmetic Preparations Against Hair Loss: A Systematic Review of Available Clinical Evidence. Healthcare, 13(4), 395. DOI: 10.3390/healthcare13040395 Caffeine as an Active Ingredient in Cosmetic Preparations Against Hair Loss: A Systematic Review of Available Clinical Evidence.
14 M.G. Davis, M.P. Piliang, W.F. Bergfeld, T.L. Caterino, B.K. Fisher, J.P. Sacha, G.J. Carr, L.T. Moulton, D.J. Whittenbarger, J.R. Schwartz, Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial. Int. J. Cosmet. Sci. 43, S14–S25(2021). DOI: 10.1111/ics.12734 Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial.
38 Chien Yin GO, Siong-See JL, Wang ECE. Telogen Effluvium – a review of the science and current obstacles. J Dermatol Sci. 2021 Mar;101(3):156-163. doi: 10.1016/j.jdermsci.2021.01.007. Epub 2021 Jan 23. PMID: 33541773. Telogen Effluvium – a review of the science and current obstacles.
39 Samrao A, Mirmirani P. Postpartum Telogen Effluvium Unmasking Traction Alopecia. Skin Appendage Disord. 2022 Jul;8(4):328-332. doi: 10.1159/000521705. Epub 2022 Jan 28. PMID: 35983466; PMCID: PMC9274946. Postpartum Telogen Effluvium Unmasking Traction Alopecia. Skin Appendage Disord.
43 Shin DH, Cha YJ, Yang KE, et al. Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles. Phytotherapy Research : PTR. 2014 Jul;28(7):1088-1095. DOI: 10.1002/ptr.5101. PMID: 24375856. Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles.
44 Fischer TW, Hipler UC, Elsner P. Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro. Int J Dermatol. 2007 Jan;46(1):27-35. doi: 10.1111/j.1365-4632.2007.03119.x. PMID: 17214716. Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro.
45 Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Minoxidil. [Updated 2024 Nov 15]. Available from: Minoxidil.
72 Alhanshali L, Buontempo M, Shapiro J, Lo Sicco K. Medication-induced hair loss: An update. J Am Acad Dermatol. 2023 Aug;89(2S):S20-S28. doi: 10.1016/j.jaad.2023.04.022. PMID: 37591561. Medication-induced hair loss: An update.

Return to → 04 Alopecia Areata

6 Elise A. Olsen, Rodney Sinclair, Maria Hordinsky, Natasha A. Mesinkovska, Neil Sadick, Jerry Shapiro, Wilma Bergfeld, Summation and recommendations for the safe and effective use of topical and oral minoxidil, Journal of the American Academy of Dermatology, Volume 93, Issue 2, 2025, Pages 457-465, ISSN 0190-9622, DOI: 10.1016/j.jaad.2025.04.016. Summation and recommendations for the safe and effective use of topical and oral minoxidil.
16 Malhotra K, Madke B. An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options. Int J Trichology. 2023 Jan-Feb;15(1):3-12. doi: 10.4103/ijt.ijt_28_21. Epub 2023 Apr 19. PMID: 37305188; PMCID: PMC10251289. An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options. Int J Trichology.
17 Raheem A, Al-Dhalimi M. Comparative Study of Trichoscopic Features of Alopecia Areata between Adults and Children and between Different Body Parts (Scalp, Beard, Eyebrow, and Moustache). Indian J Dermatol. 2024 Jul-Aug;69(4):285-291. doi: 10.4103/ijd.ijd_346_23. Epub 2024 Aug 19. PMID: 39296703; PMCID: PMC11407578. Comparative Study of Trichoscopic Features of Alopecia Areata between Adults and Children and between Different Body Parts (Scalp, Beard, Eyebrow, and Moustache).
18 Muhaidat JM, Al-Qarqaz F, Khader Y, Alshiyab DM, Alkofahi H, Almalekh M. A Retrospective Comparative Study of Two Concentrations of Intralesional Triamcinolone Acetonide in the Treatment of Patchy Alopecia Areata on the Scalp. Clin Cosmet Investig Dermatol. 2020 Nov 2;13:795-803. doi: 10.2147/CCID.S280855. PMID: 33173320; PMCID: PMC7646378. A Retrospective Comparative Study of Two Concentrations of Intralesional Triamcinolone Acetonide in the Treatment of Patchy Alopecia Areata on the Scalp.
19 Sun Y, Li Q, Zhang Y, Liu Y. Janus kinase inhibitors for alopecia areata: a review of clinical data. Front Immunol. 2025 May 13;16:1577115. doi: 10.3389/fimmu.2025.1577115. PMID: 40433365; PMCID: PMC12106550. Janus kinase inhibitors for alopecia areata: a review of clinical data.
20 Lenane P, Macarthur C, Parkin PC, Krafchik B, DeGroot J, Khambalia A, Pope E. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial. JAMA Dermatol. 2014 Jan;150(1):47-50. doi: 10.1001/jamadermatol.2013.5764. PMID: 24226568. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial.
21 Lee S, Kim BJ, Lee YB, Lee WS. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018 Oct 1;154(10):1145-1151. doi: 10.1001/jamadermatol.2018.2312. PMID: 30073292; PMCID: PMC6233743. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
22 Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017 Mar 16;3:17011. doi: 10.1038/nrdp.2017.11. PMID: 28300084; PMCID: PMC5573125. Alopecia areata.
57 Ali E, Owais R, Sheikh A, Shaikh A. Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata. Ann Med Surg (Lond). 2022 Jul 13;80:104157. doi: 10.1016/j.amsu.2022.104157. PMID: 36045780; PMCID: PMC9422172. Olumniant(Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata.
58 Blair HA. Ritlecitinib: First Approval. Drugs. 2023 Sep;83(14):1315-1321. doi: 10.1007/s40265-023-01928-y. Erratum in: Drugs. 2023 Oct;83(15):1457. doi: 10.1007/s40265-023-01956-8. PMID: 37556041; PMCID: PMC10556173. Ritlecitinib: First Approval.
59 Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the Treatment of Alopecia Areata. Drugs. 2023 Jun;83(9):761-770. doi: 10.1007/s40265-023-01873-w. Epub 2023 May 17. PMID: 37195491; PMCID: PMC10191081. Baricitinib for the Treatment of Alopecia Areata.
60 Litfulo, INN-ritlecitinib – European Medicines Agency. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. (2023 Sep 15). Retrieved 2025 Aug 20 from Litfulo, INN-ritlecitinib – European Medicines Agency.
61 TGA. (2025, July 24). OLUMIANT (Eli Lilly Australia Pty Ltd). Therapeutic Goods Administration (TGA). Retrieved 2025 Aug 20 from OLUMIANT (Eli Lilly Australia Pty Ltd). Therapeutic Goods Administration (TGA).
62 TGA. (2024, July 30). Litfulo (ritlecitinib). Therapeutic Goods Administration(TGA). Retrieved 2025 Aug 20 from Litfulo (ritlecitinib). Therapeutic Goods Administration (TGA).

Return to → 05 Scalp Inflammation & Dandruff

23 Kim GK. Seborrheic Dermatitis and Malassezia species: How Are They Related? J Clin Aesthet Dermatol. 2009 Nov;2(11):14-7. PMID: 20725575; PMCID: PMC2923939. Seborrheic Dermatitis and Malassezia species: How Are They Related?
24 Tao R, Li R, Wang R. Skin microbiome alterations in seborrheic dermatitis and dandruff: A systematic review. Exp Dermatol. 2021 Oct;30(10):1546-1553. doi: 10.1111/exd.14450. Epub 2021 Aug 27. PMID: 34415635. Skin microbiome alterations in seborrheic dermatitis and dandruff: A systematic review.
25 Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015 May 2;(5):CD008138. doi: 10.1002/14651858.CD008138.pub3. PMID: 25933684; PMCID: PMC4448221. Topical antifungals for seborrhoeic dermatitis.
26 Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995 Mar;132(3):441-5. doi: 10.1111/j.1365-2133.1995.tb08680.x. PMID: 7718463. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial.
27 Waldroup W, Scheinfeld N. Medicated shampoos for the treatment of seborrheic dermatitis. Journal of Drugs in Dermatology : JDD. 2008 Jul;7(7):699-703. PMID: 18664167. Medicated shampoos for the treatment of seborrheic dermatitis.
28 Barbosa V, Melo DF, Vañó-Galván S, Lutchmanen-Kolanthan V, Sant’Anna B, Leclerc-Mercier S, Reygagne P. A Comparative Randomized Clinical Study Assessing the Efficacy of a 1% Selenium Disulfide-Based Shampoo versus 2% Ketoconazole Shampoo in Subjects with Moderate to Severe Scalp Seborrheic Dermatitis. Skin Appendage Disord. 2024 Dec;10(6):497-504. doi: 10.1159/000539209. Epub 2024 Jun 18. PMID: 39659649; PMCID: PMC11627539. A Comparative Randomized Clinical Study Assessing the Efficacy of a 1% Selenium Disulfide-Based Shampoo versus 2% Ketoconazole Shampoo in Subjects with Moderate to Severe Scalp Seborrheic Dermatitis.
29 Dall’Oglio F, Lacarrubba F, Verzì AE, Micali G. Noncorticosteroid Combination Shampoo versus 1% Ketoconazole Shampoo for the Management of Mild-to-Moderate Seborrheic Dermatitis of the Scalp: Results from a Randomized, Investigator-Single-Blind Trial Using Clinical and Trichoscopic Evaluation. Skin Appendage Disord. 2016 Feb;1(3):126-30. doi: 10.1159/000439354. Epub 2015 Oct 17. PMID: 27171495; PMCID: PMC4857909. Noncorticosteroid Combination Shampoo versus 1% Ketoconazole Shampoo for the Management of Mild-to-Moderate Seborrheic Dermatitis of the Scalp: Results from a Randomized, Investigator-Single-Blind Trial Using Clinical and Trichoscopic Evaluation.
30 Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, Jyrkkä J, Oravilahti T, Rannanheimo PK, Verbeek JH. Topical anti‐inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD009446. DOI: 10.1002/14651858.CD009446.pub2. Accessed 21 August 2025. Topical anti‐inflammatory agents for seborrhoeic dermatitis of the face or scalp.
31 Kastarinen H, Okokon EO, Verbeek JH. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp: summary of a Cochrane Review. JAMA Dermatol. 2015 Feb;151(2):221-2. doi: 10.1001/jamadermatol.2014.3186. PMID: 25629391. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp: summary of a Cochrane Review.
32 Piérard-Franchimont C, Goffin V, Henry F, Uhoda I, Braham C, Piérard GE. Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. Int J Cosmet Sci. 2002 Oct;24(5):249-56. doi: 10.1046/j.1467-2494.2002.00145.x. PMID: 18498517. Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations.
33 Piérard-Franchimont, C., Xhauflaire-Uhoda, E., Loussouarn, G., Saint Léger, D. and Piérard, G.E. (2006), Dandruff-associated smouldering alopecia: a chronobiological assessment over 5 years. Clinical and Experimental Dermatology, 31: 23-26. doi: 10.1111/j.1365-2230.2005.02026.x Dandruff-associated smouldering alopecia: a chronobiological assessment over 5 years.
34 Hasanbeyzade S. The Effects of Zinc Pyrithione and Selenium Disulfide Shampoos on the Lesion-free Period After Treatment in Patients with Seborrheic Dermatitis. J Clin Aesthet Dermatol. 2023 May;16(5):40-42. PMID: 37288280; PMCID: PMC10243732. The Effects of Zinc Pyrithione and Selenium Disulfide Shampoos on the Lesion-free Period After Treatment in Patients with Seborrheic Dermatitis.
56 Official Journal of the European Union. (2021, October 29). COMMISSION REGULATION(EU) 2021/1902 amending Annexes II, III and V to Regulation (EC) No 1223/2009 of the European Parliament and of the Council as regards the use in cosmetic products of certain substances classified as carcinogenic, mutagenic or toxic for reproduction. EU Regulation 2021/1902

Return to → 06 Traction · Heat · Chemical

6 Elise A. Olsen, Rodney Sinclair, Maria Hordinsky, Natasha A. Mesinkovska, Neil Sadick, Jerry Shapiro, Wilma Bergfeld, Summation and recommendations for the safe and effective use of topical and oral minoxidil, Journal of the American Academy of Dermatology, Volume 93, Issue 2, 2025, Pages 457-465, ISSN 0190-9622, DOI: 10.1016/j.jaad.2025.04.016. Summation and recommendations for the safe and effective use of topical and oral minoxidil.
14 M.G. Davis, M.P. Piliang, W.F. Bergfeld, T.L. Caterino, B.K. Fisher, J.P. Sacha, G.J. Carr, L.T. Moulton, D.J. Whittenbarger, J.R. Schwartz, Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial. Int. J. Cosmet. Sci. 43, S14–S25(2021). DOI: 10.1111/ics.12734 Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial.
25 Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015 May 2;(5):CD008138. doi: 10.1002/14651858.CD008138.pub3. PMID: 25933684; PMCID: PMC4448221. Topical antifungals for seborrhoeic dermatitis.
27 Waldroup W, Scheinfeld N. Medicated shampoos for the treatment of seborrheic dermatitis. Journal of Drugs in Dermatology : JDD. 2008 Jul;7(7):699-703. PMID: 18664167. Medicated shampoos for the treatment of seborrheic dermatitis.
32 Piérard-Franchimont C, Goffin V, Henry F, Uhoda I, Braham C, Piérard GE. Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. Int J Cosmet Sci. 2002 Oct;24(5):249-56. doi: 10.1046/j.1467-2494.2002.00145.x. PMID: 18498517. Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations.
36 Billero V, Miteva M. Traction alopecia: the root of the problem. Clin Cosmet Investig Dermatol. 2018 Apr 6;11:149-159. doi: 10.2147/CCID.S137296. PMID: 29670386; PMCID: PMC5896661. Traction alopecia: the root of the problem.
41 Akingbola CO, Vyas J. Traction alopecia: A neglected entity in 2017. Indian J Dermatol Venereol Leprol. 2017 Nov-Dec;83(6):644-649. doi: 10.4103/ijdvl.IJDVL_553_16. PMID: 29035284. Traction alopecia: A neglected entity in 2017.
42 El Khatib, S., Hammoudi Halat, D., Khaled, S., Malki, A., & Alameddine, B.(2025). Novel Compounds for Hair Repair: Chemical Characterization and In Vitro Analysis of Thiol Cross-Linking Agents. Pharmaceuticals, 18(5), 632. doi: 10.3390/ph18050632 Novel Compounds for Hair Repair: Chemical Characterization and In Vitro Analysis of Thiol Cross-Linking Agents.
43 Shin DH, Cha YJ, Yang KE, et al. Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles. Phytotherapy Research : PTR. 2014 Jul;28(7):1088-1095. DOI: 10.1002/ptr.5101. PMID: 24375856. Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles.
48 Khumalo NP, Jessop S, Gumedze F, Ehrlich R. Determinants of marginal traction alopecia in African girls and women. J Am Acad Dermatol. 2008 Sep;59(3):432-8. doi: 10.1016/j.jaad.2008.05.036. PMID: 18694677. Determinants of marginal traction alopecia in African girls and women.
52 Detwiler SP, Carson JL, Woosley JT, Gambling TM, Briggaman RA. Bubble hair. Case caused by an overheating hair dryer and reproducibility in normal hair with heat. J Am Acad Dermatol. 1994 Jan;30(1):54-60. doi: 10.1016/s0190-9622(94)70008-7. PMID: 8277032. Bubble hair. Case caused by an overheating hair dryer and reproducibility in normal hair with heat.
53 Khumalo NP, Stone J, Gumedze F, McGrath E, Ngwanya MR, de Berker D. ‘Relaxers’ damage hair: evidence from amino acid analysis. J Am Acad Dermatol. 2010 Mar;62(3):402-8. doi: 10.1016/j.jaad.2009.04.061. PMID: 20159306. ‘Relaxers’ damage hair: evidence from amino acid analysis.
54 Samrao A, Price VH, Zedek D, Mirmirani P. The “Fringe Sign” – A useful clinical finding in traction alopecia of the marginal hair line. Dermatol Online J. 2011 Nov 15;17(11):1. PMID: 22136857. The”Fringe Sign” – A useful clinical finding in traction alopecia of the marginal hair line.
55 Uwakwe LN, De Souza B, Tovar-Garza A, McMichael AJ. Intralesional Triamcinolone Acetonide in the Treatment of Traction Alopecia. J Drugs Dermatol. 2020 Feb 1;19(2):128-130. doi: 10.36849/JDD.2020.4635. PMID: 32129955. Intralesional Triamcinolone Acetonide in the Treatment of Traction Alopecia.

Return to → 07 Medical Factors

6 Elise A. Olsen, Rodney Sinclair, Maria Hordinsky, Natasha A. Mesinkovska, Neil Sadick, Jerry Shapiro, Wilma Bergfeld, Summation and recommendations for the safe and effective use of topical and oral minoxidil, Journal of the American Academy of Dermatology, Volume 93, Issue 2, 2025, Pages 457-465, ISSN 0190-9622, DOI: 10.1016/j.jaad.2025.04.016. Summation and recommendations for the safe and effective use of topical and oral minoxidil.
10 Gupta AK, Charrette A. Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia. Skinmed. 2015 May-Jun;13(3):185-9. PMID: 26380504. Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia.
12 OURA, H., IINO, M., NAKAZAWA, Y., TAJIMA, M., IDETA, R., Nakaya, Y., ARASE, S. and KISHIMOTO, J. (2008), Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: A pilot, double-blind, randomized, placebo-controlled trial. The Journal of Dermatology, 35: 763-767. DOI: 10.1111/j.1346-8138.2008.00564.x Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: A pilot, double-blind, randomized, placebo-controlled trial.
13 Szendzielorz, E., & Spiewak, R. (2025). Caffeine as an Active Ingredient in Cosmetic Preparations Against Hair Loss: A Systematic Review of Available Clinical Evidence. Healthcare, 13(4), 395. DOI: 10.3390/healthcare13040395 Caffeine as an Active Ingredient in Cosmetic Preparations Against Hair Loss: A Systematic Review of Available Clinical Evidence.
14 M.G. Davis, M.P. Piliang, W.F. Bergfeld, T.L. Caterino, B.K. Fisher, J.P. Sacha, G.J. Carr, L.T. Moulton, D.J. Whittenbarger, J.R. Schwartz, Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial. Int. J. Cosmet. Sci. 43, S14–S25(2021). DOI: 10.1111/ics.12734 Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial.
43 Shin DH, Cha YJ, Yang KE, et al. Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles. Phytotherapy Research : PTR. 2014 Jul;28(7):1088-1095. DOI: 10.1002/ptr.5101. PMID: 24375856. Ginsenoside Rg3 up-regulates the expression of vascular endothelial growth factor in human dermal papilla cells and mouse hair follicles.
68 Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol. 2003 Nov;121(5):985-8. doi: 10.1046/j.1523-1747.2003.12540.x. PMID: 14708596. Decreased serum ferritin is associated with alopecia in women.
69 Harfmann KL, Bechtel MA. Hair loss in women. Clin Obstet Gynecol. 2015 Mar;58(1):185-99. doi: 10.1097/GRF.0000000000000081. PMID: 25517757. Hair loss in women.
70 van Beek N, Bodó E, Kromminga A, Gáspár E, Meyer K, Zmijewski MA, Slominski A, Wenzel BE, Paus R. Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. J Clin Endocrinol Metab. 2008 Nov;93(11):4381-8. doi: 10.1210/jc.2008-0283. Epub 2008 Aug 26. PMID: 18728176. Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation.
71 Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999 Aug 12;341(7):491-7. doi: 10.1056/NEJM199908123410706. PMID: 10441606. The biology of hair follicles.
72 Alhanshali L, Buontempo M, Shapiro J, Lo Sicco K. Medication-induced hair loss: An update. J Am Acad Dermatol. 2023 Aug;89(2S):S20-S28. doi: 10.1016/j.jaad.2023.04.022. PMID: 37591561. Medication-induced hair loss: An update.
73 Oláh A, Gherardini J, Bertolini M, Chéret J, Ponce L, Kloepper J, Bíró T, Soeberdt M, Abels C, Paus R. The Thyroid Hormone Analogue KB2115 (Eprotirome) Prolongs Human Hair Growth (Anagen) Ex Vivo. J Invest Dermatol. 2016 Aug;136(8):1711-1714. doi: 10.1016/j.jid.2016.03.033. Epub 2016 Apr 8. PMID: 27066887. The Thyroid Hormone Analogue KB2115 (Eprotirome) Prolongs Human Hair Growth (Anagen) Ex Vivo. J Invest Dermatol.
84 Telogen effluvium and associated incidence of abnormal serum ferritin, zinc, 25-hydroxy vitamin D, and thyroid-stimulating hormone. Journal of the American Academy of Dermatology, Volume 70, Issue 5, AB92 Telogen effluvium and associated incidence of abnormal serum ferritin, zinc, 25-hydroxy vitamin D, and thyroid-stimulating hormone.
85 Olsen EA, Reed KB, Cacchio PB, Caudill L. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol. 2010 Dec;63(6):991-9. doi: 10.1016/j.jaad.2009.12.006. Epub 2010 Oct 13. PMID: 20947203. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol.
86 Farooque, Umar. (2020). Telogen Effluvium: A Review of the Literature. Cureus. https://doi.org/10.7759/cureus.8320 Telogen Effluvium: A Review of the Literature.

01 / 03

What are you noticing?

select up to two

02 / 03

What’s going on?

select up to two

03 / 03

How long has this been happening?

select one

Your results